WO2006096746A1 - Proteine de liaison piegee en tant que biocapteurs - Google Patents

Proteine de liaison piegee en tant que biocapteurs Download PDF

Info

Publication number
WO2006096746A1
WO2006096746A1 PCT/US2006/008175 US2006008175W WO2006096746A1 WO 2006096746 A1 WO2006096746 A1 WO 2006096746A1 US 2006008175 W US2006008175 W US 2006008175W WO 2006096746 A1 WO2006096746 A1 WO 2006096746A1
Authority
WO
WIPO (PCT)
Prior art keywords
binding protein
binding
protein
biosensor
hydrogel
Prior art date
Application number
PCT/US2006/008175
Other languages
English (en)
Inventor
Javier Alarcon
James Bruce Pitner
Wensheng Cai
Original Assignee
Becton, Dickinson And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/077,028 external-priority patent/US20050239155A1/en
Application filed by Becton, Dickinson And Company filed Critical Becton, Dickinson And Company
Publication of WO2006096746A1 publication Critical patent/WO2006096746A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/5436—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand physically entrapped within the solid phase

Definitions

  • the invention is in the field of biotechnology. Specifically, the invention is directed to binding molecules such as binding proteins, proteins comprising reporter groups, compositions of binding proteins comprising reporter groups in analyte permeable matrices, and their use as analyte biosensors both in vitro and in vivo.
  • binding molecules such as binding proteins, proteins comprising reporter groups, compositions of binding proteins comprising reporter groups in analyte permeable matrices, and their use as analyte biosensors both in vitro and in vivo.
  • Biosensors are devices capable of providing specific quantitative or semi-quantitative analytical information using a biological recognition element.
  • the biological recognition element of a biosensor determines the selectivity, so that only the compound which has to be measured leads to a signal.
  • the selection may be based on biochemical recognition of the ligand where the chemical structure of the ligand (e.g. glucose) is unchanged, or biocatalysis in which the element catalyzes a biochemical reaction of the analyte.
  • the transducer translates the recognition of the biological recognition element into a semi-quantitative or quantitative signal.
  • Possible transducer technologies are optical, electrochemical, acoustical/mechanical or colorimetrical.
  • the optical properties that have been exploited include absorbance, fluorescence/phosphorescence, bio/chemiluminescence, reflectance, light scattering and refractive index.
  • Conventional reporter groups such as fluorescent compounds may be used, or alternatively, there is the opportunity for direct optical detection, without the need for a label.
  • Biosensors specifically designed for glucose detection that use biological elements for signal transduction typically use electrochemical or colorimetric detection of glucose oxidase activity. This method is associated with difficulties including the influence of oxygen levels, inhibitors in the blood and problems with electrodes. In addition, detection results in consumption of the analyte that can cause difficulties when measuring low glucose concentrations.
  • MBP periplasmic binding proteins
  • Hellinga, et al. reports the engineering of a glucose biosensor by introducing a fluorescent transducer into a Galactose/Glucose Binding Protein (GGBP) mutated to contain a cysteine residue, taking advantage of the large conformation changes that occur upon glucose binding.
  • GGBP Galactose/Glucose Binding Protein
  • Hellinga et al discloses that the transmission of conformational changes in mutated GGBPs can be exploited to construct integrated signal transduction functions that convert a glucose binding event into a change in fluorescence via an allosteric coupling mechanism.
  • the fluorescent transduction functions are reported to interfere minimally with the intrinsic binding properties of the sugar binding pocket in GGBP.
  • biosensors may be configured using more than one protein, each with a different binding constant, to provide accurate measurements over a wide range of glucose concentrations as disclosed by Lakowicz (US 6,197,534).
  • a biosensor containing reporter groups may have a desirable binding constant, but not result in an easily detectable signal upon analyte binding.
  • Some of the overriding factors that determine sensitivity of a particular reporter probe attached to a particular protein for the detection of a specific analyte are the nature of the specific interactions between the selected probe and amino acid residues of the protein. It is not currently possible to predict these interactions within proteins using existing computational methods, nor is it possible to employ rational design methodology to optimize the choice of reporter probes. It is currently not possible to predict the effect on either the binding constant or the selectivity based on the position of any reporter group, or amino acid substitution in the protein (or visa-versa).
  • the transduction element must be in communication with a detection device to interrogate the signal to and from the transduction element.
  • Typical methods include placing proteins within or onto the surface of optical fibers or planner waveguides using immobilization strategies.
  • immobilization strategies include, but are not limited to, entrapment of the protein within semi-permeable membranes, organic polymer matrices, or inorganic polymer matrices.
  • the immobilization strategy ultimately may determine the performance of the working biosensor.
  • Prior art details numerous problems associated with the immobilization of biological molecules. For example, many proteins undergo irreversible conformational changes, denaturing, and loss of biochemical activity.
  • Immobilized proteins can exist in a large number of possible orientations on any particular surface, for example, with some proteins oriented such that their active sites are exposed whereas others may be oriented such that there active sites are not exposed, and thus not able to undergo selective binding reactions with the analyte. Immobilized proteins are also subject to time-dependent denaturing, denaturing during immobilization, and leaching of the entrapped protein subsequent to immobilization. Therefore problems result including an inability to maintain calibration of the sensing device and signal drift. In general, binding proteins require orientational control to enable their use, thus physical absorption and random or bulk covalent surface attachment or immobilization strategies as taught in the literature generally are not successful.
  • sol-gel matrices are optically transparency, making them useful for the development of chemical and bio-chemical sensors that rely on optical transduction, for example absorption or fluorescence spectroscopic methods.
  • entrapped or immobilized binding proteins must remain able to undergo at least some analyte induced conformational change.
  • sol-gel entrapped proteins can exhibit dramatically altered binding constants, or binding constants that change over relatively short time periods or under varying environmental conditions.
  • a time dependence of the protein function while entrapped in the sol-gel matrix has been reported. This time dependence of protein function in sol-gel entrapped matrices has limited general applicability of sol-gels in biosensors for in vitro as well as in vivo use.
  • FIGURE 1 illustrates the change in fluorescence response to glucose of
  • FIGURE 2 illustrates signal enhancement of entrapped binding proteins in the absence and presence of analyte relative to solution.
  • FIGURE 3 illustrates an entrapped binding protein in the absence and presence of analyte relative to solution.
  • FIGURE 4 illustrates reversible signal from an entrapped binding protein from one embodiment of the present invention.
  • FIGURE 5 depicts a schematic representation of a crosslinked poly(ethylene glycol)
  • FIGURE 6 depicts a graph demonstrating the fluorescence signal resulting from exposure of a PEG hydrogel glucose biosensor to 100 mM glucose.
  • FIGURE 7 depicts a graph demonstrating that the fluorescence intensity of the PEG hydrogel glucose biosensor corresponds proportionally to the concentrations of glucose.
  • FIGURE 8 depicts a graph demonstrating the stability of the PEG hydrogel glucose biosensors described herein, over a 40 day period.
  • FIGURE 9 depicts a graph showing the response time of a PEG hydrogel glucose biosensor of the present invention in response to varying concentrations of ligand.
  • FIGURE 10 depicts a graph tracking the changes in glucose concentrations in vivo in a pig using the PEG hydrogel glucose biosensors of the present invention.
  • FIGURE 11 depicts a graph showing the response to varying concentrations of fatty acid by a PEG hydrogel fatty acid biosensor of the present invention.
  • FIGURE 12 depicts the binding curve of a maltose biosensor comprising a maltose binding protein (labeled with IANBD) in a hydrogel, prepared by the "one pot" method.
  • FIGURE 13 depicts the emission spectra of a maltose biosensor comprising a maltose binding protein (labeled with IANBD) in a hydrogel prepared by the "one pot” method in response to a solution of 100 mM maltose.
  • a maltose binding protein labeled with IANBD
  • FIGURE 14 depicts the binding curve of a maltose biosensor comprising a maltose binding protein (labeled with IANBD) in a hydrogel, prepared by the "two pot” method.
  • FIGURE 15 depicts the ability of a maltose biosensor, comprising a maltose binding protein (labeled with IANBD) in a hydrogel located in an optical fiber, to track changes in maltose levels.
  • a maltose biosensor comprising a maltose binding protein (labeled with IANBD) in a hydrogel located in an optical fiber, to track changes in maltose levels.
  • FIGURE 16 depicts the response of a HEMA-MAA hydrogel glucose biosensor in the presence and absence of 100 mM glucose concentration.
  • FIGURE 17 depicts the response of a HEMA-MAA hydrogel glucose biosensor at different glucose concentrations.
  • FIGURE 18 depicts the glucose response of a poly(HEMA) hydrogel glucose biosensor coated on a 0.47 mm optical fiber
  • FIGURE 19 depicts the changes in fluorescence intensity of hydrogel glucose biosensors in response to changing blood glucose levels in the glucose-controlled anesthetized pig.
  • FIGURE 20 depicts the fluorescence response (QF) of hydrogel glucose biosensors prepared by the photo crosslinking methods described herein.
  • the invention provides compositions comprising binding molecules in biosensors.
  • the invention provides a glucose biosensor including (a) a mutated binding protein and at least one reporter group attached thereto such that said reporter group provides detectable signal when said mutated binding protein is exposed to glucose and (b) a matrix permeable to analyte where the mutated glucose/galactose binding protein and the reporter group are entrapped within the matrix.
  • compositions comprising a mixture including (a) at least one binding protein and at least one reporter group attached thereto and (b) a hydrogel, dialysis membrane, sol-gel, or combinations thereof to provide for a matrix permeable to analyte wherein the binding protein and the reporter group are entrapped within the matrix.
  • the invention also provides a composition and device including (a) a mutated maltose binding protein (MBP) and at least one reporter group attached thereto such that the reporter group provides a detectable signal when the mutated MBP is bound to maltose and wherein the MBP includes a cysteine present at position 337 and (b) a matrix permeable to maltose wherein the mutated MBP and the reporter group are entrapped within the matrix.
  • MBP mutated maltose binding protein
  • the invention further provides a device and compositions thereof suitable for in vivo use including (a) a mutated glucose/galactose binding protein and at least one reporter group attached thereto such that the reporter group provides a detectable and reversible signal when the mutated glucose/galactose binding protein is exposed to varying glucose concentrations and (b) a matrix permeable to analyte wherein the mutated glucose/galactose binding protein and the reporter group are entrapped within the matrix.
  • the present invention also relates to a biosensor comprising a polymeric hydrogel and a binding molecule.
  • the binding molecule is covalently attached to the hydrogel, and the binding molecule must be capable of generating a detectable signal upon target binding.
  • the biosensor is a glucose biosensor and comprises poly(ethylene glycol) and a glucose binding protein covalently attached thereto.
  • the biosensor is a glucose biosensor and comprises copolymers of hydroxyethylmethacrylate and methacrylic acid and a glucose binding protein covalently attached thereto.
  • the invention also relates to methods of making and using biosensors.
  • biosensor generally refers to a device that uses specific biochemical reactions mediated by isolated enzymes, immunosystems, tissues, organelles or whole cells to detect chemical compounds, usually by electrical, thermal or optical signals.
  • the compositions of the present invention must be able to function as biosensors.
  • biosensor is used to mean a composition, device or product that provides information regarding the local biological environment in which the product, device or composition is located.
  • a "biological environment” is used to mean an in vivo, in situ or in vitro setting comprising or capable of supporting tissue, cells, organs, body fluids, single- celled organisms, multicellular organisms, or portions thereof. The cells, tissue, organs or organisms, etc.
  • biological settings include, but are not limited to, in vitro cell culture settings, in vivo settings in or on an organism (such as an implant), a diagnostic or treatment setting, tool or machine, such as a DNA microarray or blood in a dialysis machine.
  • an organism such as an implant
  • diagnostic or treatment setting such as a DNA microarray or blood in a dialysis machine.
  • tool or machine such as a DNA microarray or blood in a dialysis machine.
  • the type of biological environment in which the biosensor can be placed should not limit the present invention.
  • compositions of the present invention comprise a binding molecule.
  • a binding molecule is a molecule that binds to a ligand or complementary binding partner in a specific manner.
  • a binding molecule can be a protein, such as a receptor, enzyme, antibody (or fragment thereof), or other binding protein.
  • the binding molecule can also be a polynucleotide that can bind to other polynucleotides.
  • target ligands may include, but are not limited to, monosaccharides, disaccharides, polysaccharides, amino acids, oligopeptides, polypeptides, proteoglycans, glycoprotein, nucleic acids, oligonucleotides, lipids, fatty acids, natural or synthetic polymers, and small molecular weight compounds such as drugs or drug candidates.
  • the binding molecule within the compositions of the present invention is a binding protein.
  • binding proteins generally refers to proteins which interact with specific analytes in a manner capable of transducing or providing a detectable and or reversible signal differentiable either from when analyte is not present, analyte is present in varying concentrations over time, or in a concentration-dependent manner, by means of the methods described.
  • the transduction event includes continuous, programmed, and episodic means, including one-time or reusable applications. Reversible signal transduction may be instantaneous or may be time-dependent providing a correlation with the presence or concentration of analyte is established.
  • binding proteins include, but are not limited to, periplasmic binding proteins such as galactose/glucose binding protein (GGBP), maltose binding protein (MBP), ribose binding protein (RBP), arabinose binding protein (ABP), dipeptide binding protein (DPBP), glutamine binding protein (QBP), iron binding protein (FeBP), histidine binding protein (HBP), phosphate binding protein (PhosBP), and oligopeptide binding protein (OppA) or derivatives thereof.
  • GGBP galactose/glucose binding protein
  • MBP maltose binding protein
  • RBP arabinose binding protein
  • DBP dipeptide binding protein
  • QBP glutamine binding protein
  • FeBP iron binding protein
  • HBP histidine binding protein
  • PhosBP phosphate binding protein
  • OppA oligopeptide binding protein
  • Another example of a binding molecule is fatty acid binding protein (FABP) or derivatives thereof.
  • FABP fatty acid binding protein
  • GGBP is a single chain protein consisting of two globular ⁇ / ⁇ domains that are connected by three strands to form a hinge. The binding site is located in the cleft between the two domains. When glucose enters the binding site, GGBP undergoes a conformational change, centered at the hinge, which brings the two domains together and entraps glucose in the binding site.
  • X-ray crystallographic structures have been determined for the closed form of GGBP from E. coli (N. K. Vyas, M. N. Vyas, F. A.
  • the wild type E. coli GGBP DNA and amino acid sequence can be found at www.ncbi.nlm.nih.gov/entrez/ accession number D90885 (genomic clone) and accession number 23052 (amino acid sequence).
  • the GGBP may be from E. coli.
  • the binding proteins may be wild-type (native), or they may be a non-wild-type protein, provided that the proteins still bind to a target ligand in a specific manner.
  • a "non-wild-type protein” is a protein that shares substantial sequence identity with the wild-type protein. Examples of non-wild-type proteins include, but are not limited to, mutant and fusion proteins.
  • "Mutated binding protein” (for example "mutated GGBP") as used herein refers to binding proteins from bacteria containing amino acid(s) which have been substituted for, deleted from, or added to the amino acid(s) present in naturally occurring protein.
  • the mutant binding proteins may be mutated to bind more than one ligand in a specific manner. Indeed, the mutant binding proteins may possess specificity towards its wild-type ligand and another target ligand.
  • Exemplary mutations of binding proteins include the addition or substitution of cysteine groups, non-naturally occurring amino acids (Turcatti, et al. J. Bio. Chem. 1996271, 33, 19991-19998) and replacement of substantially non-reactive amino acids with reactive amino acids to provide for the covalent attachment of electrochemical or photo-responsive reporter groups.
  • the mutations in the non-wild-type binding proteins may serve one or more of several purposes. For example, a naturally occurring protein may be mutated in order to change the long-term stability of the protein; to conjugate the protein to a particular entrapment matrix, polymer; or to provide binding sites for detectable reporter groups, or to adjust its binding constant with respect to a particular analyte, or combinations thereof.
  • Exemplary mutations of the GGBP protein include a cysteine substituted for a lysine at position 11(Kl 1C), a cysteine substituted for aspartic acid at position 14 (D14C), a cysteine substituted for valine at position 19 (V 19C), a cysteine substituted for asparagine at position 43 (N43C), a cysteine substituted for a glycine at position 74 (G74C), a cysteine substituted for a tyrosine at position 107 (Y 107C), a cysteine substituted for threonine at position 110 (Tl 10C), a cysteine substituted for serine at position 112 (Sl 12C), a double mutant including a cysteine substituted for a serine at position 112 and serine substituted for an leucine at position 238(Sl 12C/L238S), a cysteine substituted for a lysine at position 113 (Kl 13C
  • mutant binding proteins may be able to only bind a ligand or ligands that the wild-type binding protein does not bind.
  • Methods of generating mutant proteins, in general, are well-known in the art. For example, Looger, et al., (Nature 423 (6936): 185-190 (2003)), which is hereby incorporated by reference, disclose methods for re-designing binding sites within periplasmic binding proteins that provide new ligand-binding properties for the proteins. These mutant binding proteins retain the ability to undergo conformational change, which can produce a directly generated signal upon ligand- binding. By introducing between 5 and 17 amino acid changes, Looger, et al.
  • mutant proteins each with new selectivities for TNT (trinitrotoluene), L-lactate, or serotonin.
  • TNT trinitrotoluene
  • L-lactate L-lactate binding proteins
  • serotonin a group consisting of TNT-binding proteins, L-lactate binding proteins, or serotonin.
  • Looger et al. generated L-lactate binding proteins from ABP, GGBP, RBP, HBP and QBP.
  • These and other mutant binding proteins could be attached to the matrices of the present invention, such as hydrogels, to prepare a biosensor specific for the target ligands to which the proteins bind, and are within the scope of the present invention.
  • a fusion protein is used herein as it is in the art, and methods of generating fusion proteins are well-known in the art.
  • fusion protein derivatives of binding proteins may include fusions of binding proteins with fluorescent proteins such as green fluorescent protein (GFP) or dsRed.
  • GFP green fluorescent protein
  • dsRed fusion proteins that can be used in this present invention are described in pending United States application serial number 10/721,091, filed November 26, 2003, the entirety of which is hereby incorporated by reference.
  • fusion proteins contemplated for use in the present invention may be engineered or mutated to have a histidine tag on the protein's N- terminus, C-terminus, or both termini. Histidine fusion proteins are widely used in the molecular biology field to aid in the purification of proteins. Exemplary tagging systems produce proteins with a tag containing about six histidines, with such tagging not compromising the binding activity of the binding protein.
  • the binding molecule e.g., binding proteins
  • the binding molecule are functionally derivatized prior to, or simultaneously with, their incorporation into the matrix, such as a hydrogel.
  • the term "functionally derivatized” is used to mean a molecule such as a protein, polypeptide or oligopeptide that has been modified with the addition of a polymerizable reactive group such that the functionally derivatized molecule can act as a monomer during the polymerization of the matrix, e.g., a hydrogel.
  • one embodiment of the current invention relates to methods of making a biosensor, with the methods comprising polymerizing functionally derivatized binding proteins with one or more monomers to produce a crosslinked polymeric hydrogel biosensor.
  • This method of forming the biosensor by polymerizing a functionally derivatized binding protein with monomer constituents of the hydrogel is, in essence, one particular embodiment of a method of covalently attaching a binding protein to the matrix, such as a hydrogel.
  • NAS N-acryloxysuccinimide
  • vinyl azlactone acrylamidopropyl pyridyl disulfide
  • N-(acrylamidopropyl)maleimide N-(acrylamidopropyl)maleimide
  • the functional derivatization may occur anywhere on the molecule that is amenable to accepting the reactive groups, such as a lysine or a cysteine residue on a polypeptide chain; and the functional derivatization may occur at one or more places on the protein or peptide chain.
  • a binding protein is functionally derivatized to comprise acrylate functional groups.
  • the act of "functionally derivatizing" a protein would comprise adding, e.g., through a conjugation reaction, a polymerizable reactive group to a molecule, such as a protein, polypeptide, oligopeptide dipeptide or even a single amino acid.
  • the invention also contemplates that non-wild-type proteins may also be functionally derivatized.
  • a functionally derivatized protein may also be non-wild-type protein, as previously described herein, such as a mutant protein.
  • N-acryloyl succinimide NAS is reacted with lysine residues on a binding protein to provide an acrylate functionally derivatized binding protein described herein.
  • analyte and binding molecule act as binding partners.
  • the term "associates” or “binds” as used herein refers to specific binding. Affinity of specific binding can be assessed by calculating a relative binding constant such as, but not limited to, dissociation constant (Kd).
  • Kd dissociation constant
  • the Kd may be calculated as the concentration of free analyte at which half the binding molecule is bound, or vice versa.
  • the Kd values for the binding partners are preferably between about 0.0001 mM to about 30 mM.
  • the entrapped binding proteins of the present invention may be used in an in vitro or in vivo analyte assay which, for example, is capable of following the kinetics of biological reactions involving an analyte, such as glucose, as well as in clinical assays, and food or beverage industrial testing.
  • analyte such as glucose
  • the concentration of the binding protein in the matrix is less than the Kd of the protein in solution.
  • one aspect of the present invention relates to methods of altering the affinity of the binding molecules towards their targets.
  • the present invention relates to methods of decreasing the affinity of a binding protein containing biosensor, as measured, for example, by the biosensor's apparent Kd, towards its target analyte.
  • apparent Kd is used to mean the overall measured dissociation constant of the biosensor towards an analyte, as assessed by the directly generated signal of the biosensor in response to the analyte.
  • the present invention relates to methods of altering the affinity of the binding molecule towards its target analyte, or altering the selectivity of a biosensor comprising binding molecule.
  • the entrapment of a GGBP within a matrix may decrease the affinity of the protein-containing biosensor towards glucose, thus increasing the apparent Kd of the biosensor, in relation to free GGBP in solution.
  • one embodiment of the present invention relates to a biosensor comprising a binding molecule wherein the biosensor has an apparent Kd of at least about one order of magnitude greater than the Kd of the free binding molecule, i.e., a binding molecule not entrapped within or on a matrix, in solution.
  • a specific embodiment of the present invention includes biosensors for either glucose or maltose detection, with apparent Kd of at least one order of magnitude greater than the Kd of free GGBP or MBP, respectively.
  • the biosensors comprised of a matrix and a binding molecule must be capable of providing a detectable signal upon target ligand binding to the binding molecule.
  • provide a detectable signal refers to the ability to recognize a change in a property of a reporter group within the biosensor in a manner that enables the detection of ligand-protein binding.
  • the binding molecules may comprise one or more "reporter groups,” e.g., a fluorescent protein or dye, that are responsible for generating the detectable signal which is altered upon a change in binding molecule conformation or reporter group environment which occurs, for example, upon analyte binding.
  • the biosensor will generate a signal directly upon binding of the target ligand to the binding molecule.
  • generating a signal directly upon binding is used to mean that the act of binding of the analyte to the binding molecule itself is responsible for generating the detectable signal, without any additional reactions or processes.
  • a directly generated signal is a signal that is produced by the reporter group itself and not the matrix, e.g., hydrogel.
  • a directly generated signal is not meant to include a signal that is generated from a chemical reaction that produces a product or byproduct which would then be measured, nor is a directly generated signal used to mean a signal that is generated from competitive binding to a labeled analyte, as disclosed in Russell, R. J. and Pishko, M. V., "A fluorescence-based glucose biosensor using concanavalin A and Dextran encapsulated in a polyethylene glycol) hydrogel, Anal. Chem., 71: 3126-3132 (1999), and in United States Patent No. 6,475,750.
  • a directly generated signal can be a signal that is produced when a conformational change occurs in a binding protein, such as when the protein binds specifically to its target
  • the binding molecule is a protein that comprises a reporter group that is a luminescent label.
  • the luminescent label may be a fluorescent label or a phosphorescent label.
  • One particular embodiment of the present invention comprises the use of fluorescent labels, which may be excited to fluoresce by exposure to certain wavelengths of light.
  • the reporter group attached to the binding protein is a fluorophore.
  • fluorophore refers to a molecule that absorbs energy and then emits light.
  • fluorophores useful as reporter groups in this invention include fluorescein, coumarins, rhodamines, 5-TMRIA (tetramethylrhodamine-5- iodoacetamide), Quantum Red TM, Texas RedTM, Cy3, N-((2-iodoacetoxy)ethyl)-N- methyl)amino-7-nitrobenzoxadiazole (IANBD), 6-acryloyl-2-dimethylaminonaphthalene (acrylodan), pyrene, Lucifer Yellow, Cy5, Dapoxyl® (2-bromoacetamidoethyl)sulfonamide, (N-(4,4-difluoro-l,3,5,7-tetramethyl- 4-bora-3a,
  • fluorophore reporter group Many detectable intrinsic properties of a fluorophore reporter group may be monitored to detect glucose binding. Some of these properties which can exhibit changes upon glucose binding include fluorescence lifetime, fluorescence intensity, fluorescence anisotropy or polarization, and spectral shifts of fluorescence emission. Changes in these fluorophore properties may be induced from changes in the fluorophore environment such as those resulting from changes in protein conformation. Environment-sensitive dyes such as IANBD are particularly useful in this respect. Other changes of fluorophore properties may result from interactions with the analyte itself or from interactions with a second reporter group, for example when FRET (fluorescence resonance energy transfer) is used to monitor changes in distance between two fluorophores.
  • FRET fluorescence resonance energy transfer
  • Fluorophores that operate at long excitation and emission wavelengths are useful when the molecular sensor is to be used in vivo, for example, incorporated into an implantable biosensor device (the skin being opaque below 600 nm).
  • thiol-reactive derivatives of Cy-5 can be prepared for example as taught by H. J. Gruber, et al, Bioconjugate Chem., (2000), JJ,, 161- 166.
  • Conjugates containing these fluorophores, for example, attached at various cysteine mutants constructed in binding proteins can be screened to identify which results in the largest change in fluorescence upon analyte binding.
  • the binding molecule is a mutant protein is a mutant GGBP comprising a luminescent label as the reporter group
  • the binding of glucose to this fluorescent-labeled GGBP should, in turn, alter the measured luminescence of the reporter group, and this change in the detectable characteristics may be due to an alteration in the environment of the label bound to the mutated GGBP.
  • reporter groups besides luminescent labels, may be used to provide the detectable signal.
  • electrochemical reporter groups could be used wherein an alteration in the environment of the reporter will give rise to a change in the redox state thereof. Such a change may be detected using an electrode.
  • other spectroscopically detectable labels for example labels detectable by NMR (nuclear magnetic resonance), may be used.
  • the reporter group may be attached to the binding molecule by any conventional means known in the art.
  • the reporter group may be attached via amines or carboxyl residues on the protein.
  • covalent coupling via thiol groups on cysteine residues may be exploited.
  • cysteines located at position 11, position 14, position 19, position 43, position 74, position 107, position 110, position 112, position 113, position 137, position 149, position 152, position 213, position 216, position 238, position 287, and position 292 may be used.
  • Any thiol-reactive group known in the art may be used for attaching reporter groups such as fluorophores to an engineered or mutated protein's cysteine.
  • reporter groups such as fluorophores
  • an iodoacetamide, bromoacetamide, or maleimide are well known thiol-reactive moieties that may be used for this purpose.
  • compositions, devices and methods of the present invention also comprise a matrix that entraps the binding molecules.
  • matrix refers to essentially a three-dimensional environment which has at least one binding molecule immobilized therein for the purpose of measuring a detectable signal from ligand-protein interaction.
  • the relationship between the constituents of the matrix and the binding molecule include, but are not limited to covalent, ionic, and Van der WaIs interactions and combinations thereof.
  • the spatial relationship between the matrix and binding molecules includes heterogeneous and homogeneous distribution within and or upon any or all of the matrix volume.
  • the matrix may be comprised of organic, inorganic, glass, metal, plastic, or combinations thereof.
  • the matrix may also allow the biosensor to be incorporated at the distal end of a fiber or other small minimally invasive probe to be inserted within the tissue of a patient, to enable an episodic, continuous, or programmed reading to the patient.
  • Information from the biosensor to the patient may be provided, for example, by telemetry, visual, audio, or other means known in the art, for example, as taught in US 5,517,313, US 5,910,661, US 5,894,351, and US 5,342,789 as well as in Beach, R.D., et al. IEEE Transactions on Instrumentation and Measurement (1999) 48, 6, p.1239-1245.
  • Information includes electrical, mechanical, and actinic radiation suitable for deriving analyte concentration or change in concentration, as is suitable.
  • the binding molecule should be entrapped within a matrix, such as a hydrogel, which may then be used as an implantable device.
  • a matrix such as a hydrogel
  • the term “entrap” and variations thereof is used interchangeably with “encapsulate” and is used to mean that the binding molecule is immobilized within or on the constituents of the matrix.
  • the matrix can be in any desirable form or shape including one or more of disk, cylinder, patch, nanoparticle, microsphere, porous polymer, open cell foam, and combinations thereof, providing it permits permeability to analyte.
  • the matrix additionally prevents leaching of the biosensor.
  • the matrix permits light from optical sources or any other interrogating light to or from the reporter group to pass through the biosensor.
  • the biosensor When used in an in vivo application, the biosensor will be exposed to a substantially physiological range of analyte and determination or detection of a change in analyte concentration would be desired whereas the determination or detection includes continuous, programmed, and episodic detection means.
  • the envisaged in vivo biosensor comprises at least one mutated binding protein in an analyte permeable entrapping or encapsulating matrix such that the mutated binding protein provides a detectable and reversible signal when the mutated binding protein is exposed to varying analyte concentrations, and the detectable and reversible signal can be related to the concentration of the analyte.
  • the implantable biosensors may, in some embodiments, be implanted into or below the skin of a mammal's epidermal-dermal junction to interact with the interstitial fluid, tissue, or other biological fluids.
  • Information from the implant to the patient may be provided, for example, by telemetry, visual, audio, or other means known in the art, as previously stated.
  • the matrix is prepared from biocompatible materials or incorporates materials capable of minimizing adverse reactions with the body. Adverse reactions for implants include inflammation, protein fouling, tissue necrosis, immune response and leaching of toxic materials. Such materials or treatments are well known and practiced in the art, for example as taught by Quinn, C. P.; Pathak, C. P.; Heller, A.; Hubbell, J.
  • the binding molecule may be entrapped or encapsulated within a matrix that is derived substantially from a hydrogel.
  • hydrogel is used to indicate a water-insoluble, water-containing material.
  • Numerous hydrogels may be used in the present invention.
  • the hydrogels may be, for example, polysaccharides such as agarose, dextran, carrageenan, alginic acid, starch, cellulose, or derivatives of these such as, e.g., carboxymethyl derivatives, or a water- swellable organic polymer such as, e.g., polyvinyl alcohol, polyacrylic acid, polyacrylamide, polyethylene glycol, copolymers of styrene and maleic anhydride, copolymers of vinyl ether and maleic anhydride and derivates thereof.
  • Derivatives providing for covalently crosslinked networks are preferred. Synthesis and biomedical and pharmaceutical applications of hydrogels based on, comprising polypeptides, have been described by a number of researchers.
  • An exemplary hydrogel matrix derived from a water-soluble, UV crosslinkable polymer comprises polyvinyl alcohol),N-methyl-4(4'-formylstyryl)pyridinium methosulphate acetal (CAS Reg. No. [107845-59-0]) available from PolyScience Warrington, PA. [0061]
  • the polymers that are to be used in the matrices, such as hydrogels, used in the present invention may be functionalized. Of course, polymers used in other matrices may also be functionalized.
  • the polymers or monomers comprising the polymers should possess reactive groups such that the polymeric matrices, such as hydrogels, are amenable to chemical reactions, e.g., covalent attachment.
  • a "reactive group” is a chemical group that can chemically react with a second group.
  • the reactive group of the polymer or monomers comprising the polymer may itself be an entire chemical entity or it may be a portion of an entire chemical entity, including, but not limited to single atoms or ions.
  • the second group with which the reactive group is capable of reacting can be the same or different from the reactive group of the polymer or monomers comprising the polymers.
  • reactive groups include, but are not limited to, halogens, amines, amides, aldehydes, acrylates, vinyls, hydroxyls and carboxyls.
  • the polymers or monomers comprising the polymers of the hydrogel should be functionalized with carboxylic acid, sulfate, hydroxy or amine groups.
  • the polymers or monomers comprising the polymers of the hydrogel are functionalized with one or more acrylate groups.
  • the acrylate functional groups are terminal groups.
  • the reactive groups of the polymers or monomers comprising the polymers of the matrix may be reactive with any component of the matrix portion of the biosensor, such as, but not limited to, another polymer or monomer within the matrix, a binding protein and an additive.
  • the core of any hydrogels used in the present invention should comprise polymers to form a polymeric hydrogel.
  • polymer herein is used to refer to molecules composed of multiple monomer units.
  • Suitable polymers which may be used in the present invention include, but are not limited to, one or more of the polymers selected from the group consisting of poly(vinyl alcohol), polyacrylamide, poly (N-vinyl pyrolidone), poly(ethylene oxide) (PEO), hydrolysed polyacrylonitrile, polyacrylic acid, polymethacrylic acid, poly(hydroxyethyl methacrylate), polyurethane polyethylene amine, poly(ethylene glycol) (PEG), cellulose, cellulose acetate, carboxy methyl cellulose, alginic acid, pectinic acid, hyaluronic acid, heparin, heparin sulfate, chitosan, carboxymethyl chitosan, chitin, collagen, pullul
  • the polymers of the matrix may also comprise polymers of two or more distinct monomers.
  • Monomers used to create copolymers for use in the matrices include, but are not limited to acrylate, methacrylate, methacrylic acid, alkylacrylates, phenylacrylates, hydroxyalkylacrylates, hydroxyalkylmethacrylates, aminoalkylacrylates, aminoalkylmethacrylates, alkyl quaternary salts of aminoalkylacrylamides, alkyl quaternary salts of aminoalkylmethacrylamides, and combinations thereof.
  • Polymer components of the matrix may, of course, include blends of other polymers.
  • a hydrogel biosensor comprises a binding molecule and a matrix, with the matrix comprising a hydrogel of copolymers of (hydroxyethyl methacrylate) and methacrylic acid.
  • a hydrogel biosensor comprises a binding molecule and a matrix hydrogel of copolymers of (hydroxyethyl methacrylate), methacrylic acid, and alkyl quaternary salts of methacrylamides.
  • the polymers used in the matrices can be modified to contain nucleophilic or electrophilic groups.
  • the polymers used in the present invention may further comprise polyfunctional small molecules that do not contain repeating monomer units but are polyfunctional, i.e., containing two or more nucleophilic or electrophilic functional groups. These polyfunctional groups may readily be incorporated into conventional polymers by multiple covalent bond-forming reactions.
  • PEG can be modified to contain one or more amino groups to provide a nucleophilic group.
  • Examples of other polymers that contain one or more nucleophilic groups include, but are not limited to, polyamines such as ethylenediamine, tetramethylenediamine, pentamethylenediamine, hexamethylenediamine, Z»w-(2-hydroxyethyl)amine, t ⁇ -(2-aminoethyl)amine, and /ra-(2-aminoethyl)amine.
  • polyamines such as ethylenediamine, tetramethylenediamine, pentamethylenediamine, hexamethylenediamine, Z»w-(2-hydroxyethyl)amine, t ⁇ -(2-aminoethyl)amine, and /ra-(2-aminoethyl)amine.
  • electrophilic groups include but are not limited to, succinimide esters, epoxides, hydroxybenzotriazole esters, oxycarbonylimidazoles, nitrophenyl carbonates, tresylates, mesylates, tosylates, carboxylates, and isocyanates.
  • the composition comprises a Zr ⁇ -amine-terminated poly(ethylene glycol).
  • the polymers should be capable of crosslinking, either physically or chemically, to form a matrix, such as a hydrogel.
  • Physical crosslinking includes, but is not limited to, such non-chemical processes as radiation treatment such as electron beams, gamma rays, x-rays, ultraviolet light, anionic and cationic treatments.
  • the crosslinking of the polymers may also comprise chemical crosslinking, such as covalent crosslinking.
  • a chemical crosslinking system may include, but is not limited to, the use of enzymes, which is well- known in the art.
  • Another example of the chemical covalent crosslinking comprises the use of peroxide. Chemical crosslinking may occur when a crosslinking reagent reacts with at least two portions of a polymer to create a three-dimensional network. Covalent crosslinking may also occur when multifunctional monomers are used during the crosslinking process.
  • an acrylate monomer may be polymerized with a bifunctional acrylate monomer to form a crosslinked polymer.
  • Any crosslinking reagent will be suitable for the present invention, provided the crosslinking reagent will at least partially dissolve in water or an organic solvent and can form the crosslinked polymer.
  • the polymer is an amine-terminated PEG
  • the crosslinking reagent should be capable of reacting with the PEG- amine groups and be substantially soluble in water.
  • (hydroxyethyl methacrylate) and methacrylic acid monomers can be polymerized with poly(ethylene glycol)-bis-alklyacrylate crosslinking agent in water or in dimethylformide to form polymeric hydrogels.
  • the crosslinking reagent can be a molecule containing an electrophilic group. Examples of electrophilic groups have been described herein.
  • the crosslinking reagent can be a molecule containing a nucleophilic group. It is understood that one skilled in the art can exchange the nucleophilic and electrophilic functional groups as described above without deviating from the scope of the present embodiment.
  • the binding molecule can provide the requisite nucleophilic and electrophilic functional groups.
  • the nucleophilic and electrophilic functional groups may be present as naturally occurring amino acids in the protein, or may be introduced to the protein using chemical techniques described herein.
  • binding molecules can be covalently attached to or non-covalently entrapped or encapsulated within a matrix, such as, but not limited to, a hydrogel.
  • the binding molecules are covalently attached to, i.e., entrapped within, a hydrogel.
  • the covalent attachment of the binding molecule to the hydrogel should not interfere with the binding of the binding molecule to the target ligand.
  • the covalent attachment of the binding molecule to the hydrogel should be resistant to degradation.
  • the functional group in one embodiment, a polymer or other component of the hydrogel serves to couple the binding molecule to the hydrogel. The coupling of the binding molecule to the hydrogel can be accomplished in any number of ways.
  • coupling reactions between the hydrogel and binding molecule include, but are not limited to, diazonium coupling, isothiocyano coupling, hydrazide coupling, amide formation, disulfide coupling, maleic anhydride coupling, thiolactone coupling, and dichlotriazine coupling. These coupling reactions between two functional groups are well documented, and are considered well known to those skilled in the art.
  • an amino functional group in a binding molecule can be covalently coupled to a carboxyl functional group of one or more components of a hydrogel using coupling agents such as l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) or dicyclohexylcarbodiimide (DCC).
  • coupling agents such as l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) or dicyclohexylcarbodiimide (DCC).
  • coupling agents include, but are not limited to, benzyl carbamate and hydroxybenzotriazole, or bifunctional reagents such as N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), sulfo-LC-SPDP, succinimidyl 4-(N- maleimidomethyl) cyclohexane-1-carboxylate (SMCC), sulfo-SMCC, m-maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), sulfo-MBS, N-succinimidyl (4-iodoacethyl) aminobenzoate (SIAB), sulfo-SIAB, succinimidyl 4-(p-maleimidophenyl) butyrate (SMPB), sulfo-SMPB, dithiobis (succinimidylpropionate), 3,3'-di
  • reagents that have several pendant functional groups such as thiol, hydroxyl, acyl chloride, sulfate, sulfonyl chloride, phosphate, phosphate chloride, and imide can also be conjugated to hydrogel using the above coupling agents and crosslinking agents.
  • the covalent attachment of a binding molecule to a the matrix can also be accomplished via photo polymerization and crosslinking either concurrently or subsequently to formation of the matrix.
  • the photo polymerization and crosslinking of the polymer to binding molecule includes the use of photoinitiators that generate reactive species, such as free radicals or cationic centers, upon exposure to an energy source.
  • photoinitiators that may be used include, but are not limited to, peroxides, ketones, and azo compounds.
  • Specific examples of photoinitiators include, but are not limited to, 2-hydroxy- 2-methylpropiophenone, benzoin, and 2,2-dimethoxy-2-phenyl-acetophenone, and the like.
  • the energy from the energy source may be from anywhere in the electromagnetic spectrum, such as, but not limited to, radio waves, infrared light, visible light, ultraviolet light, X-rays and gamma rays.
  • the energy source used to polymerize and crosslink a binding protein to a hydrogel is ultraviolet light.
  • the covalent coupling of a binding molecule to the matrix can take place after hydrogel formation or during hydrogel formation.
  • the polymer and the binding molecule can be mixed with a crosslinking component, used in the formation of a hydrogel, in the presence of water to fo ⁇ n the hydrogel biosensor of the present invention in a single or "one pot" process.
  • the reaction can take place at room temperature or at an elevated temperature compatible with the binding molecule.
  • the resultant binding activity of the hydrogel-attached binding molecule may be affected, for example, by binding molecule loading concentration, polymer concentration, and the molar ratio of nucleophilic groups to electrophilic groups, or cationic groups to either neutral or anionic groups.
  • the binding molecule When the binding molecule is a binding protein, the protein may be randomly immobilized within the hydrogel.
  • amino groups from polymer components of a hydrogel are not only able to react with electrophilic groups to form the hydrogel, but they also prevent or inhibit excessive multiple site covalent attachment of the binding protein. Maintaining excess amino groups in the hydrogel components has been observed to maintain the binding protein activity of the biosensor.
  • the binding molecule or a functionally derivatized binding molecule may function as a monomeric component of, and co-polymerize with, other monomeric components of the hydrogel.
  • an acrylate functional group can be covalently attached to a binding molecule to provide a co- polymerizable component of a hydrogel.
  • the binding molecule can be covalently coupled to the matrix, such as a hydrogel, after matrix formation, creating a biosensor via a "two pot" process.
  • a hydrogel is first formed via the polymerization and crosslinking reaction, and unreacted monomers are washed from the hydrogel.
  • the hydrogel is then placed in a buffer solution containing a binding molecule, and the solution is allowed to diffuse into the hydrogel.
  • a homobifunctional crosslinker comprising amine-reactive groups may be added to the buffer solution to couple a carboxyl functional group of the hydrogel with a carboxyl functional group of a binding molecule.
  • the homobifunctional crosslinker can be the same or different from the crosslinker used when polymerizing and crosslinking the components that form the matrix.
  • Preparing the biosensor via the "two pot" method may also be accomplished by adding a crosslinker to the matrix, such as a hydrogel, after its formation, but before adding a . binding molecule.
  • the crosslinker is allowed to react with the matrix and the matrix is, in turn, contacted with a buffer solution containing the binding molecule.
  • the coupling reaction can take place at a temperature compatible with the binding molecule.
  • the amount of binding molecule attached to the matrices and the binding activity of the binding molecule may be controlled by pH.
  • a coupling reaction with a pH of about 7.0 should favor electrophilic groups reacting with the N-terminal amine of a protein, whereas a coupling reaction pH of about 9.0 should favor electrophilic groups reacting with lysine amine groups of a protein.
  • the binding molecule can also be covalently coupled to a preformed cross-linked matrix through site specific coupling.
  • site specific coupling to the hydrogel may be provided using free thiol groups at cysteine sites of the protein.
  • An example of such a covalent coupling is described in United States application serial no. 10/428,295 filed May 2, 2003, which is hereby incorporated by reference.
  • the matrix is first prepared with an excess of nucleophilic groups, such as amines and is then covalently coupled with a binding molecule using a heterobifunctional crosslinker such as, but not limited to sulfosuccinimidyl 6-[3'(2-pyridyldithio)-propionamide] hexanoate (sulfo-LC-SPDP).
  • a heterobifunctional crosslinker such as, but not limited to sulfosuccinimidyl 6-[3'(2-pyridyldithio)-propionamide] hexanoate (sulfo-LC-SPDP).
  • Sulfo- LC-SPDP reacts with amine and thiol groups, respectively, of the matrix and binding molecule.
  • one or more hydrogels in water is added the mutated binding protein in an aqueous buffer solution having a pH in the range of about 4 to about 10 depending on the protein.
  • Subsequent curing of the matrix for example crosslinking, provides physical form.
  • a conventional fabrication process e.g. block casting, reverse emulsion polymerization, screen or contact printing, fluid- bed coating and dip or spin coating
  • matrices in various configurations e.g. granulates, nanoparticles, microparticles, monoliths, and thick and thin films
  • a thin film of the hydrogel biosensor can be prepared in sheet form or deposited on a sheet that is capable of being subsequently cut into strips for in vitro use.
  • binding proteins may be physically entrapped or encapsulated within the aforementioned matrices, such as, but not limited to, the aforementioned hydrogels.
  • Such methods of physically entrapping binding molecules include one and two pot methods previously described herein, without the coupling reaction between the binding molecule and components of the matrix.
  • the physically entrapped or encapsulated binding protein hydrogel biosensor can be prepared in sheet form or deposited on a sheet that is capable of being subsequently cut into strips for in vitro use.
  • the matrix such as a hydrogel, may further comprise one or more additives.
  • one or more additives that may be included in the matrix include, but are not limited to, carbohydrates such as monosaccharides, disaccharides, polysaccharides, amino acids, oligopeptides, polypeptides, proteoglycans, glycoprotein, nucleic acids, oligonucleotides, lipids, fatty acids, natural or synthetic polymers, small molecular weight compounds such as antibiotics, drugs or drug candidates, and derivatives thereof.
  • the hydrogel biosensors further comprise at least one carbohydrate or alcohol derivative thereof.
  • the hydrogel biosensor includes at least one compound selected from the group consisting of allose, altrose, glucose, mannose, gulose, idose, galactose, talose, ribulose, fructose, sorbose, tagatose, sucrose, lactose, maltose, isomaltose, cellobiose, trehalose, mannitol, sorbitol, xylitol, maltitol, dextrose, and lactitol.
  • Such additives can provide enhanced storage stability of a binding molecule hydrogel biosensor.
  • a trehalose additive is added to a binding protein hydrogel biosensor to provide improved lyophilized storage stability described herein.
  • the matrix may, in one embodiment, be comprised of modified sol-gels.
  • Modified sol-gels includes at least partial cured (or gelled) preparations comprised of permeable metal oxide glass structures containing in addition to the sol-gel precursor materials, preferably one or more organic components which hydrolytically condense along with the sol-gel precursor such that the resultant sol-gel matrix imparts properties suitable for, by example, implantation. Suitable properties include low volume shrinkage over time, resistance to cracking and other physical defects, maintenance of protein function, and compatibility with the protein and or reporter group, and compatibility with the animal or subject to which it may be implanted.
  • Suitable organic materials include polyols such as glycerol, ethylene glycol, propylene glycol, polyethylene glycol, and the like for example, as taught by Gill and Ballesteros Journal of the American Chemical Society 1998, 120(34), 8587-8598. It is understood that those skilled in the art can appreciate the attributes described are generally not predictable for a given protein/sol-gel/reporter group combination, thus optimization of sol-gel precursor, organic component and protein solution materials may be expected for any given binding protein-reporter pair. It has been found by the applicants that such optimization may provide for unexpected enhanced signal, shifted binding constants, improved physical performance attributes of the matrix, and combinations thereof relative to that of other matrices or aqueous solutions thereof.
  • Sol-gel matrices useful for the present invention include material prepared by conventional, well-known sol-gel methods and include inorganic material, organic material or mixed organic/inorganic material.
  • the materials used to produce the sol-gel can include, but are not limited to, aluminates, aluminosilicates and titanates.
  • hydrolytically condensable siloxane refers to sol-gel precursors having a total of four substituents, at least one, preferably two, and most preferably three or four of the substituents being alkoxy substituents covalently bound to silicone through oxygen and mixtures thereof.
  • At least one of the remaining substituents preferably is covalently bound to silicone through carbon, and whereas the remaining substituent contains organic functionality from alkyl, aryl, amine, amide, thiol, cyano, carboxyl, ester, olef ⁇ nic, epoxy, silyl, nitro, and halogen.
  • one or more of hydrolytically condensable siloxane is hydrolyzed in water, either spontaneously or under acid or base catalysis to form derivatives with an organic polyol component present in a molar amount relative to the hydrolytically condensable siloxane up to about 10:1 to 1:10, preferably to about 5:1 to 1:5, and most preferably to about 1:1.
  • an organic polyol component present in a molar amount relative to the hydrolytically condensable siloxane up to about 10:1 to 1:10, preferably to about 5:1 to 1:5, and most preferably to about 1:1.
  • To this mixture prior to final gellation, is added the mutated binding protein in an aqueous buffer solution having a pH in the range of about 4 to about 10 depending on the protein. At least partial condensation reactions give rise to the final matrices.
  • the hydrolytically condensable siloxane hydrolyzed in water is mixed with a water soluble polymer component.
  • Suitable water soluble polymers include polyvinyl alcohol (PVA), poly-(maleic acid co-olefin) sodium salt (PMSA), poly-(vinylsulfonic acid) sodium salt (PVSA), and polyvinyl pyrollidone (PVP).
  • PoIy- maleic acid co-olefin
  • styrene vinyl ether
  • C1-C8 olefins and salts thereof for example, sodium, potassium, ammonium, tetraakylammonium, and the like.
  • the water soluble polymer component is from 0 to about 30% by weight of the sol-gel composition.
  • the hydrolytically condensable siloxane hydrolyzed in water, either spontaneously or under acid or base catalysis to form derivatives with the organic polyol is mixed with one or more functionalized silicone additives (FSA) in amounts from 0 to about 0.6% mole ratios to hydrolytically condensable siloxane.
  • FSA's include alkyl derivatives: for example, methyltrimethoxysilane (MTMOS): amine derivatives: for example, 3-aminopropyl triethoxysilane (ATEOS); and bis silane derivatives: for example, (bis(3-methyldimethoxysilil)propyl) polypropylene oxide (BIS).
  • both the water soluble polymer component and the f ⁇ mctionalized silicone additive are mixed together with the hydrolytically condensable siloxane hydrolyzed in water, either spontaneously or under acid or base catalysis to form derivatives with the organic polyol, to provide for a matrix suitable for entrapment or encapsulation of the binding protein.
  • a conventional fabrication process e.g. block casting, reverse emulsion polymerization, screen or contact printing, fluid-bed coating and dip or spin coating
  • the matrix such as a hydrogel
  • the dialysis membranes can be constructed to physically encapsulate or entrap the hydrogel matrix containing the binding molecule. Covalent attachment of the matrix and/or the binding molecule to the dialysis membrane is considered within the scope of the as described embodiment.
  • the membrane should be chosen based on its molecular weight cut-off such that analytes of interest can readily permeate the membrane whilst high molecular weight materials would be restricted from entering, or in the case of the mutated binding proteins, leaving the membrane matrix.
  • the molecular weight cut-off required would be such as to meet the afore-mentioned requirement and is within the skill of one familiar with this art.
  • membranes having molecular weight cut-off between about 1000 to about 25,000 Daltons are suitable.
  • matrices in various configurations and shapes suitable for use in vitro and in vivo can be prepared.
  • matrices containing the binding protein and reporter group be combinations of one or more hydrogel, sol-gel, and dialysis membranes.
  • a protein entrapped or encapsulated within a hydrogel or sol gel can be placed within a dialysis membrane of a suitable shape and size as would provide for implantation within a subject, or to manipulate mass-transport properties or permeablity of the analytes with respect to the matrix.
  • the matrix entrapped or encapsulated binding molecule biosensors of this invention are capable of measuring or detecting micromolar (10 "6 molar) to molar analyte concentrations without reagent consumption.
  • their sensitivity to analyte may enable the biosensors to be used to measure the low analyte concentrations known to be present in low volume samples of interstitial fluid.
  • the implantable biosensors may, in some embodiments, be implanted into or below the skin of a mammal's epidermal- dermal junction to interact with the interstitial fluid, tissue, or other biological fluids.
  • a binding protein biosensor of the present invention may provide for the means to monitor analyte continuously, episodically, or "on-demand" as would be appropriate to the user or to the treatment of a condition.
  • the present invention also relates to methods of detecting the presence of an analyte (ligand) in a sample using the biosensors of the present invention.
  • analyte ligand
  • the terms "ligand” and “analyte” are used interchangeably and are used to indicate the molecule to which the binding molecule of the biosensors will specifically bind.
  • the analyte or ligand measured in the methods described herein is not labeled with a reporter group.
  • a sample can be any environment that may be suspected of containing the analyte to be measured.
  • a sample includes, but is not limited to, a solution, a cell, a body fluid, a tissue or portion thereof, and an organ or portion thereof.
  • the cell can be a prokaryotic or eukaryotic cell, for example, an animal cell.
  • animal cells include, but are not limited to, insect, avian, and mammalian such as, for example, bovine, equine, porcine, canine, feline, human, and nonhuman primates.
  • the scope of the invention should not be limited by the cell type assayed.
  • biological fluids to be assayed include, but are not limited to, blood, urine, saliva, synovial fluid, interstitial fluid, cerebrospinal fluid, lymphatic fluids, semen, ocular fluid, bile and amniotic fluid.
  • subject and “patient” are used interchangeably herein and are used to mean an animal, particularly a mammal, more particularly a human or nonhuman primate.
  • the biosensors of the present invention may be contacted with analyte-free solutions (control), such as buffers, and the directly generated signal measured.
  • control such as buffers
  • the value of the fluorescence measured may be, but is not limited to, intensity, rate-based or lifetime.
  • the fluorescent measurement can, in turn, be directly or indirectly tied to the concentration of measured analyte.
  • the biosensors can be contacted with a sample suspected of containing an analyte to be measured, and the intensity of the directly generated signal is measured at least once. The sequence in measuring the intensity of the control and experimental signals is not important and can be performed in any order.
  • any differences in the generated signals are an indication of the presence or absence of the analyte in the sample or control. Furthermore, measurements of the generated signal can be taken either continuously, episodically, or sequentially to monitor changes in the concentration of the analyte in the sample. Once the control or baseline signal is established, the subsequently measured signals can be measured continuously or at discrete times.
  • the comparison of the signals can be qualitative or quantitative. Furthermore, the quantitative differences can be relative or absolute. Of course, the differences in signal may be equal to zero, indicating the absence of the analyte sought.
  • the quantity may simply be the measured signal without any additional measurements or manipulations. Alternatively, the difference in signals may be manipulated mathematically or in an algorithm, with the algorithm designed to correlate the measured signal value to the quantity of analyte in the sample.
  • the quantity may be expressed as a difference, percentage or ratio of the measured value of the analyte to a measured value of another compound including, but not limited to, a standard.
  • the difference may be negative, indicating a decrease in the amount of measured analyte.
  • the quantity may also be expressed as a difference or ratio of the analyte to itself, measured at a different point in time.
  • Fluorescence emission spectra of mutated, labeled protein was measured using an SLM Aminco fiuorimeter (Ontario, Canada) with slit settings of 8 and 4 for excitation and settings of 5 and 5 on the MC250 emission monochromator to compare the ligand-binding performance of the entrapped fluorophore-labeled proteins in various matrices to the performance of the same proteins in solution.
  • the initial fluorescence emission intensity is defined as I 0 .
  • the relative ratio of the emission intensity maxima in the presence of the protein's respective ligand (I f ) to the ligand's absence (I 0 ) is defined as ⁇ F.
  • such a dimensionless value may also be expressed as a ratio of signal in the presence of ligand to a fixed or known quantity of ligand instead of an absence of ligand.
  • a value defined as Qf the ratio of fluorescence at a saturated or infinite ligand concentration (Fj nf ) and fluorescence at zero ligand concentration (F 0 ), may be used. Saturated or infinite ligand concentration may be approximated using a ligand concentration above the equilibrium dissociation constant of the binding molecule.
  • ⁇ F and Qf are used interchangeably herein and are intended to represent essentially the same dimensionless value.
  • Binding constants were determined by titration of increasing concentrations of glucose into a protein solution with mixing following each addition of glucose. Slit settings were the same as listed above. The Kd was dete ⁇ nined from the following relationships as adapted from Pisarchick and Thompson (1990):
  • F fluorescence intensity
  • Fj nf fluorescence at infinity
  • F 0 fluorescence at zero glucose
  • x free concentration of glucose ([Glc] free ) as determined by the relationship:
  • Example 1 Expression of Mutant GGBP without Histidine Tags
  • GGBP is coded by the MgIB-I gene in E. coll This protein was altered by introducing the amino acid cysteine at various positions through site- directed mutagenesis of the MgIB-I gene. These proteins were then expressed in E. coli and purified.
  • Cassette mutagenesis of MgIB-I was accomplished as follows.
  • the wild-type MgIB-I gene was cloned into a pTZ18R vector (Dr. Anthony Cass, Imperial College, London, England).
  • Mutant plasmids were generated from this parent plasmid using cassette mutagenesis producing randomized amino acid sequences, essentially as described by Kunkel (1991) and cloned in E. coli JM109 (Promega Life Science, Madison, WI). Mutant plasmids were identified by sequencing. The mutant protein was induced in JMl 09 and purified as described below.
  • coli JM 109 colony containing the mutant plasmid was grown overnight at 37°C with shaking (220 rpm) in LB broth containing 50 ⁇ g/mL ampicillin (LB/Amp). The overnight growth was diluted 1:100 in 1 L fresh LB/Amp and was incubated at 37 0 C with shaking until the OD ⁇ oo of the culture was 0.3-0.5. Expression of the mutant was induced by the addition of ImM IPTG (Life Technologies, Gaithersburg, MD) final concentration with continued incubation and shaking at 37°C for 4-6 hours. The cells were harvested by centrifugation (10,000 x g, 10 min, 4°C).
  • the mutant protein was harvested by osmotic shock and was purified by column chromatography.
  • the cell pellet was resuspended in a sucrose buffer (30 mM Tris-HCL pH 8.0, 20% sucrose, ImM EDTA), incubated at room temperature for 10 min, and then centrifuged (4000 x g, 15 min, 4°C). The supernatant was poured off and kept on ice.
  • the cell pellet was resuspended, and 10 mL ice cold, sterile deionized H 2 O was repeated, and the suspension was incubated on ice and centrifuged.
  • the remaining supernatant was pooled with the other collected supernatants and was centrifuged once again (12,000 x g, 10 min, 4°C).
  • the pooled shockate was filtered through a 0.8 ⁇ m and then a 0.45 ⁇ m filter.
  • Streptomycin sulfate Sigma Chemical Co., St. Louis, MO
  • 5% w/v was added to the shockate and was stirred once for 30 min followed by centrifugation (12,000 x g, 10 min, 4°C).
  • the shockate was then concentrated using the Amicon Centriprep 10 (10,000 MWCO) filters (Charlotte, NC) and dialyzed overnight against 5 mM Tris-HCl pH 8.0, 1 mM MgCl 2 .
  • the dialyzed shockate was centrifuged (12,000 x g, 30 min, 4°C). The resulting supernatant was added to a pre-equilibrated DEAE Fast Flow Sepharose column (Amersham Pharmacia Biotech, Piscataway, NJ) at 0.5 mL/min. The column was washed with 5-10 column volumes. A linear gradient from 0-0.2 M NaCl was applied to the column and fractions were collected. The mutant protein containing fractions were identified by SDS-PAGE with Coomassie Brilliant Blue staining (mw. Approx. 32 WDa).
  • Example 2 Expression of Mutant GGBP with Histidine Tags
  • GGBP mutants were engineered by either site-directed mutagenesis or the cassette mutagenesis.
  • Site-directed mutagenesis was performed to alter individual amino acids in the pQE70 vector by replacing one amino acid with another, specifically chosen amino acid.
  • the cassette mutagenesis method (Kunkel 1991) was performed to randomize amino acids in a specified region of the GGBP gene.
  • the mutated cassettes were then subcloned into the pQE70 expression vector.
  • the pGGBP-His plasmid contained the GGBP gene cloned into the pQE70 expression vector (Qiagen, Valencia, CA). This construct places six histidine residues on the C-terminus of the GGBP gene. E.
  • coli strain SGl 3009 was used to over express mutant GGBP-His following standard procedures (Qiagen). After over expression of a 250 mL culture, the cells were collected by centrifugation (6000 rpm) and resuspended in 25 mL bugbuster (Novagen, Madison, WI). Lysozyme (25 mg was added to the lysate and the mixture was gently mixed at room temperature (RT) for 30 min. Clear lysate was produced by centrifugation (6000 rpm) and to this, 0.5 ml imidizole (1 M) and 3 ml of Ni-NTA beads (Qiagen) was added.
  • the mutant GGBP-His was eluted from the beads by adding 5 mL solution (160 mM imidazole, 1 MNaCl, 10 mM Tris, pH 8.0) and mixing for 15 min.
  • the protein solution was immediately filtered through a Centriplus YM-100 filter (Amicon, Charlotte, NC) and then concentrated to 1-3 mg/ml using a Centriplus YM- 10 filter.
  • the protein was dialyzed overnight against 2 L of storage solution (1 M NaCl, 10 mM Tris, 50 mM NaPO 4, pH 8.0).
  • Example 3 Labeling of a Binding Protein with a Reporter Group
  • This example describes generically the labeling of binding protein with reporter probe.
  • An aliquot of mutant GGBP containing cysteine (4.0 nmol) in PBS was treated with 2 mM dithiothreitol (5 ⁇ L, 10 nmol) for 30 min.
  • a stock solution of N,N'-dimethyl-N- (iodoacetyl)-N'-(7-nitrobenz-2-oxa-l,3-diazol-4-yl)ethylenediamine (IANBD amide, 0.5 mg) was prepared in DMSO (100 ⁇ L, 11.9 mM) and 3.36 ⁇ L (40 nmol) was added to the protein. The reaction proceeded at room temperature for 4 h on a Dynal rotamix in the dark. The labeled protein was purified by gel filtration on a NAP-5 column (Amersham Pharmacia).
  • FIG. 1 illustrates the change in fluorescence response to glucose concentration of a representative example, A213C/L238C NBD amide GGBP H 6 in solution. Table 1 summarizes the change in fluorescence of various GGBP mutants labeled with reporter groups, including reporting groups having either excitation or emission maximum of at least 600 nanometers.
  • Table 2 summarizes the change in fluorescence, and determined Kd values of mutations of one, two, three, and four amino acid substitutions. This data clearly shows mutations of the GGBP labeled with a reporter group can provide desirable attributes as glucose biosensors. The data shows the mutation-reporter group relationship for the samples tested.
  • Example 4 Immobilization of a Binding Protein
  • GMSC glycerol modified silicate condensate
  • TEOS tetraethoxyorthosilicate
  • TMOS tetramethoxyorthosilicate
  • Preferred conditions were found using an interval of 10 to 30 minutes between hydrolysis and glycerol addition, a pH range of between 0.5 and 1, and a 1:1 mole ratio of TEOS to glycerol.
  • the following describes a modified procedure of Gill and Ballesteros for a TEOS-based glycerol modified silicate condensate (GMSC) preparation using the following ratios of reagents: TEOS or TMOS:1; H2O:1, Methanols, Glycerols.
  • TEOS or TMOS in methanol was added to a flask and cooled to 0 0 C over ice. Next 0.6M HCl was added drop-wise to the solution. After 20 minutes of stirring, glycerol was added drop- wise.
  • the reaction was warmed slowly over 1-2 hours to 20 - 25 0 C. Following this the reaction vessel was heated further and maintained at a temperature range of 60 - 70 0 C under nitrogen for between 36 and 42 hours. The optimal time was 40 hours. Incomplete glyceration was indicated by an observable phase separation for reactions stopped before 36 hours. Reactions maintained beyond 42 hours produced GMSC sol-gel monoliths with greatly reduced physical properties, for example, increased brittleness. Following the 40 hour reaction at 60 - 70 0 C, the solution volume was reduced by rotary evaporation until it was viscous and transparent, at which point methanol was added to the solution in a 4:1 ratio by weight. This GMSC solution proved to be stable and provided consistent results for several months when stored at freezer temperature.
  • GMSC sol-gel monoliths were not brittle and had shrinkage of about 8 % after curing at 4 0 C at 50% relative humidity for 2 weeks (% shrinkage was the average of changes in diameter and length measured with a microcaliper and compared to original mold dimensions).
  • This example describes further optimization of physical properties by GMSC sol- gels in which glycerol has been partly substituted with either ethylene glycol (EG) or polyethylene glycol (PEG).
  • Ethylene glycol (EG) was evaluated as a substitute for glycerol in mixtures where the ratio of glycerol and EG was varied but the mole ratio of total glycerol and EG was maintained constant relative to other reagents.
  • Sol-gel monoliths were prepared by the procedure described in the preceding example, cured for two weeks at 4 0 C and 50% relative humidity and their % shrinkage was determined and stated in Table 3. %Shrinkage is defined as the average of the decrease in length and diameter versus original dimensions. Monoliths used for determination of shrinkage had no protein/fluorophore present. For fluorescence measurements, the samples listed in Table 1 were prepared containing H 152 GGBP-H6 NBD (from Example 3) as will be described shortly.
  • Example 6 Entrapment of Binding Proteins in Sol-Gel
  • This example describes the addition of polymer and organic polyol additives to optimize the GMSC sol-gels for entrapping binding proteins to both maintain and enhance their spectral properties upon ligand binding.
  • the binding proteins were labeled with a fluorophore (as described in example 3).
  • the protein solutions were added during the final hydrolysis/gelling step described previously to produce final concentrations of 2-4 ⁇ M protein within the sol-gel.
  • the polymer additives and FSA' s were obtained from Sigma- Aldrich Chemicals (St. Louis, MO). Polymer additives were evaluated in amounts between 0 to about 30wt.
  • Functionalized silicone additives were evaluated as additives to the GMSC sol-gels in amounts from 0 to about 0.6% mole ratio.
  • rotary evaporation of the GMSC reagent to remove methanol from its storage solution was followed by reconstitution in water in a 1:1 ratio by weight.
  • 800 ⁇ L of buffer (HEPES, PBS or Tris) with a premixed water soluble polymer additive was added along with any FSA-modified GMSC.
  • GMSC-BIS was prepared by the same procedure as the TEOS-based GMSC, but with substitution of (Bis(3- methyldimethoxysilyl)pro ⁇ yl) polypropylene oxide for TEOS.
  • GMSC-MTMOS and GMSC- ATEOS were prepared similarly except that the hydrolysis was carried out with either 10% of the amount of acid, or no acid in the hydrolysis step, respectively compared to the TEOS- based GMSC procedure.
  • Fluorescence emission was measured with a Varian Gary Eclipse scanning fluorometer with microwell plate adapter (Varian Instruments, Victoria, Australia). Excitation was at 475 nm and emission recorded from 500 to 600 nm, typically monitoring emission maximum peak fluorescence. Slit widths were 5 nm for excitation and 10 nm for emission.
  • the I 0 spectra for each experiment were normalized to a maxima of 1.0.
  • the figure shows about 2-3 -fold enhancement of ⁇ F obtained for the optimized sol-gel matrices containing binding protein when exposed to analyte in comparison to protein in solution.
  • emission maximum may be shifted for sol-gel entrapped protein-reporter group samples as compared to solution.
  • these modified sol-gel matrices provide improved physical properties as shown in entry 4 of Table 3.
  • Table 4 shows an approximate range of components of formulations giving improved response for each of the individual proteins evaluated.
  • Example 7 Entrapment of Mutant GGBP in UV-crosslinked Hydrogel
  • This example describes the entrapment of GGBP Hl 52C in UV cross-linked hydrogel matrix and the effect of the matrix on the fluorescence change and binding affinity.
  • SbQ-PVA from Polysciences Inc. was added 100 ul of PBS buffer and mixed for one hour to mix in a rotary mixer. 80 ul of this solution was then mixed with 20 ul of labeled protein. Final protein concentration was spectroscopically determined to be 0.15 mg/ml. After mixing, aliquots were dispensed into 96-well plates and dried in a chamber maintained at 20% humidity for 12h followed by curing with UV light.
  • Figure 3 shows the ability of the mutated protein matrix to respond to the analyte in a manner, and with a sensitivity, equivalent to that obtained in solution.
  • the Kd of the entrapped protein was comparable to that obtained in solution.
  • Example 8 Immobilization of Binding Protein within a Dialysis Membrane
  • This example describes the immobilization of a biosensor of the instant invention into a dialysis membrane matrix and the ability of the matrix to provide reversible and continuous readings.
  • GGBP L238C/A213C protein (2 ⁇ M in PBS buffer) entrapped within a dialysis membrane having a molecular cut-off of 3500 Daltons affixed to the distal end of the fiber. Solutions were prepared containing PBS buffer, 2mM, and 2OmM glucose in PBS buffer.
  • Example 9 Preparation of a Hydrogel Glucose Biosensor by one pot method
  • the GGBP mutant E149C/A213R/L238S was labeled with N-((2-(iodoacetoxy)ethyl)-N-methyl)amino-7- nitrobenz-2-oxa-l,3-diazole (IANBD) (Molecular Probes, Eugene, OR) and purified to provide a protein concentration of 52.7 ⁇ M, and a dye/protein ratio 1.37.
  • IANBD N-((2-(iodoacetoxy)ethyl)-N-methyl)amino-7- nitrobenz-2-oxa-l,3-diazole
  • FIG. 5 illustrates the reaction scheme for hydrogel formation and protein immobilization. After the reaction was complete, the formed hydrogel sheet was punched into 5 mm diameter disks with a dermal biopsy punch. AU the disks were then soaked in PBS buffer (pH 7.4) for two days to wash away any unreacted monomer and protein.
  • FIG. 7 illustrates the changes in fluorescence response to glucose concentration of a representative sample of hydrogel disks prepared by the methods of the present invention.
  • the fluorescence increased with the increase of glucose concentration in the range of 0 to 100 mM glucose.
  • the glucose binding constant K d for the hydrogel biosensor was calculated as about 17 mM, which is similar to the binding constant of the free binding protein towards glucose in solution (12 mM). The Kd was determined from the following relationships
  • Example 10 Preparation of a Hydrogel Glucose Biosensor by the two pot method
  • F fluorescence intensity
  • F Inf fluorescence at infinite glucose concentration
  • Fo fluorescence at zero glucose
  • x is the glucose concentration.
  • Example 10 Preparation of a Hydrogel Glucose Biosensor by the two pot method
  • This example describes the coupling of the binding molecule to blank hydrogel disks.
  • the immobilization chemistry is also illustrated in Figure 5.
  • the hydrogel was prepared first in absence of binding protein with excess of amino groups.
  • the binding protein was coupled to the hydrogel matrix through a bifunctional crosslinker.
  • a typical example of this two pot system is illustrated as follows: 100.3 mg of 8-arm PEG-NH 2 was dissolved in 2 mL PBS buffer (pH 7.4) in a 15 mL polypropylene conical tube and was mixed with 98.2 mg BTC-PEG-BTC in 1.96 mL PBS buffer (pH 7.4). The mixture was vortexed and injected between two glass plates separated by a 2 mm spacer. The glass plates were clamped together and the reaction was continued at room temperature for at least two hours. After the reaction was complete, the hydrogel sheet was punched into 5 mm diameter disks using a dermal biopsy punch. The blank disks were soaked in 30 mL PBS (pH 7.4) for two days to wash away any monomer residuals.
  • the glucose responsiveness of the hydrogel disks was tested.
  • the hydrogel biosensors were placed in the wells of a black 96 well plate along with 180 ⁇ L PBS buffer per disk, and the initial fluorescence intensities were measured using a CytoFluor fluorescence multi-well plate reader (excitation and emission filters were centered at 485 run and 530 nm, respectively).
  • 20 ⁇ L of 1 M glucose /water solution was added into each well, providing a final glucose concentration of 100 rnM.
  • the fluorescence intensity changes were recorded again after the solution was equilibrated for 20 minutes to allow glucose to completely diffuse into the hydrogel disks and bind with GGBP.
  • the protein binding response is defined as a change in fluorescence intensity, QF, which is the ratio of the fluorescence intensity of the hydrogel biosensor disks in the presence of 100 mM glucose concentration to the fluorescence intensity of the hydrogel biosensor disks in the absence of glucose.
  • QF a change in fluorescence intensity
  • Example 11 Coupling binding protein to hydrogel through site specific attachment
  • the binding protein was coupled to the hydrogel randomly and primarily through one or more lysine sites of the protein.
  • This example describes the selective attachment of a binding protein to a hydrogel through thiol groups at cysteine sites of the protein.
  • Six PEG blank disks were prepared by the method described Example 2. These blank disks were soaked in ImL PBS buffer (pH 7.4) in a 2 mL cryogenic vial. Next, 4.9 mg of solid Sulfo-LC-SPDP (Pierce Biotechnology, Inc) was added to the mixture, and the reaction was continued at room temperature for one hour.
  • Example 12 Effect of the binding protein concentration and cross-linker to polymer ratio on the glucose binding fluorescence response of the hydrogel biosensor
  • Hydrogel biosensors comprising varying amounts of NBD-labeled E149C/A213R/L238S GGBP were prepared by the methods illustrated in Example 1 and were tested for their glucose response using a CytoFluor fluorescence multi-well plate reader.
  • Table 6 displays the binding response of the hydrogel biosensors over a range of concentrations of binding proteins. Over an initial protein concentration range, from about 4 to about 25 ⁇ M, the binding responses are very similar, suggesting that the immobilized binding proteins were able to undergo glucose-induced conformational changes, regardless of the concentration of the binding protein.
  • Example 13 Stability of the hydrogel glucose sensor
  • This example illustrates the stability of hydrogel disks prepared by the method of Example 1. Thirty hydrogel disks with immobilized NBD-labeled GGBP were stored in 20 mL PBS solution (pH 7.4) at room temperature. At varying time intervals, the hydrogel biosensor disks were taken out and the glucose binding response (QF) was determined. The results are depicted in Figure 8. The hydrogel disks showed a stable glucose response for more than one month.
  • Example 14 Binding protein immobilized in hydrogel crosslinked by 6-arm PEG- NH 2 with BTC-PEG-BTC
  • This example illustrates that other multi-arm PEG amines, in addition to 8-arm PEG-NH 2 , can be crosslinked into a hydrogel and used to covalently immobilize a binding protein.
  • Example 15 Binding protein immobilized in hydrogel crosslinked by 8-arm PEG- NH 2 WUh BS 3
  • binding molecules can also be covalently immobilized in a hydrogel crosslinked by 8-arm PEG-NH 2 , using non-PEG bifunctional crosslinkers.
  • Example 16 Hydrogel glucose biosensor on optical fiber
  • This example illustrates the use of a hydrogel with binding protein coated on an optical fiber as a device for continuous monitoring glucose concentration in vitro and in vivo.
  • a solution of 25.7 mg of 8-arm PEG-NH 2 in 0.3 niL PBS buffer (pH 7.4) in a 1.5 mL Eppendorf vial was mixed with 200 ⁇ L of NBD-labeled E149C/A231R/L238S GGBP in PBS buffer (protein concentration is 125.5 ⁇ M with dye/protein ratio 0.9).
  • FIG. 10 An example of a fluorometer is described in United States application serial no. 10/721,797, filed November 26, 2003, which is hereby incorporated by reference.
  • the fluorometer was equipped with a 470 nm LED light source and a dichroic filter to reflect the 470 nm excitation towards the input end of the fiber and to transmit the fluorescence from the fiber towards a 550 nm bandpass filter leading to a single photon counting photomultiplier tube detector.
  • Glass aspheric lenses were used both for beam collimation and to focus light into the fibers and onto the detectors.
  • Figure 9 depicts the fluorescence response of the fiber optic sensor following its immersion into solutions of the indicated glucose concentrations (0, 30, and 100 mM glucose).
  • ADIFAB AcryloDated Intestinal Fatty Acid Binding Protein with dye/protein ratio approximately 1.0, Molecular Probes
  • buffer 50 mM Tris, 1 mM EDTA, 0.05% azide, pH 8.0
  • the binding protein solution 210 ⁇ L was combined with 21 mg of 8-arm PEG-NH 2 (10,000 MW, Nektar) in a 1.5 mL Eppendorf vial.
  • the mixture of 8-arm PEG-NH 2 and binding protein was further mixed with 18 mg of BTC- PEG-BTC (3,400 MW, Nektar) in 180 ⁇ L PBS buffer (pH 7.4) and vortexed.
  • FIG. 11 depicts the fluorescence response of the hydrogel disks to a wide range of arachadonic acid concentrations.
  • the hydrogel sensor responded to FA (fatty acid, e.g., arachadonic acid) with a shift of fluorescence emission wavelength from 432 nm to 486 nm. Increasing FA concentration caused an increase in , the emission intensity at 486 nm.
  • FA fatty acid, e.g., arachadonic acid
  • the MBP mutant S337C was labeled with N-((2- (iodoacetoxy)ethyl)-N-methyl)amino-7-nitrobenz-2-oxa-l,3-diazole (IA ⁇ BD) (according to the procedure of Gilardi, et al., Anal Chem. 66:3840-7 (1994)) and purified to provide a protein concentration of 13.8 ⁇ M, and a dye/protein ratio of 2. An aliquot of 30 mg of 6- arm PEG-NH 2 (10,000 MW, Sunbio Inc., Orinda, CA) was dissolved in 300 ⁇ L of the above NBD-labeled MBP in PBS buffer.
  • IA ⁇ BD N-((2- (iodoacetoxy)ethyl)-N-methyl)amino-7-nitrobenz-2-oxa-l,3-diazole
  • the mixture was vortexed before and after adding 13.5 mg of BTC-PEG-BTC in 135 ⁇ L PBS buffer (pH 7.4) and was injected immediately between two glass plates separated by a 1 mm spacer. Hydrogel formation was complete in approximately 5 minutes. The glass plates were clamped together and the reaction was continued at room temperature for at least two hours. During the reaction, the benzotriazolyl carbonate groups from BTC-PEG-BTC react with amino groups of the 6-arm PEG-NH 2 and the amino groups of MBP, forming carbamate bonds. After the reaction was complete, the formed hydrogel sheet was punched into 4 mm diameter disks with a dermal biopsy punch. All the disks were then soaked in PBS buffer (pH 7.4) for two days to wash away any unreacted monomer and protein.
  • the maltose response of the formed hydrogel disk was tested in a 96 well plate in the presence of different maltose concentrations using a Varian Gary Eclipse fluorometer with an excitation wavelength of 475 nm and emission scanned between 500 and 600 nm. The fluorescence intensity at wavelength of 540 nm was read. The results are shown in Figure 12, which demonstrates that fluorescence increased with the increase of maltose concentration in the range of 0 to about 12.6 mM maltose.
  • the maltose binding constant K d for the hydrogel biosensor was calculated to be 1.94 mM, using the methods of calculation described in Example 9. In comparison, the Kd of the same mutant maltose binding protein is 0.062mM [Gilardi].
  • the encapsulation or entrapment of binding protein caused a shift of more than an order of magnitude in Kd compared to solution.
  • the QF of hydrogel biosensors was also measured.
  • the hydrogel biosensors were placed in the wells of a white 96 well plate along with 180 ⁇ L PBS buffer per disk, and the initial fluorescence intensities were measured using a Varian Cary Eclipse fluorometer with an excitation wavelength of 475 nm and emission scanned between 500 and 600 nm. Next, 20 ⁇ L of 1 M maltose/water solution was added into each well, providing a final maltose concentration of 100 mM.
  • Example 19 Preparation of a Hydrogel Maltose Biosensor by the Two-Pot Method.
  • the hydrogel was prepared first in absence of binding protein with excess of amino groups.
  • the binding protein was coupled to the hydrogel matrix through a bifunctional crosslinker.
  • a typical example of this two pot system is illustrated as follows: 30 mg of 6- arm PEG-NH 2 was dissolved in 300 ⁇ L PBS buffer (pH 7.4) in a 1.5 mL Eppendorf vial and was mixed with 13.5 mg BTC-PEG-BTC in 135 ⁇ L PBS buffer (pH 7.4). The mixture was vortexed and injected between two glass plates separated by a 1 mm spacer. The glass plates were clamped together and the reaction was continued at room temperature for at least two hours.
  • the hydrogel sheet was punched into 1 mm diameter disks using a dermal biopsy punch.
  • the blank disks were soaked in 30 mL PBS (pH 7.4) for two days to wash away any monomer residuals.
  • PBS pH 7.4
  • To couple the binding proteins to the blank hydrogel disks blank disks were removed from the PBS and soaked in a 1.7 mg/mL solution of BS 3 in PBS buffer in a 2 mL cryogenic vial. This reaction was continued for 15 minutes at room temperature. The disks were then taken out and rinsed briefly with PBS buffer, and soaked in 200 ⁇ L of NBD-labeled S337C MBP protein (13.2 ⁇ M with a dye/protein ratio of 2).
  • the MBP protein was allowed to couple to the hydrogel matrix for at least two hours. AU of the disks were then soaked in PBS buffer (pH 7.4) for two days to extract unattached proteins.
  • the maltose response of the hydrogel disks, prepared according to the two-pot method was tested in the presence of different maltose concentrations in a 96 well plate using a Varian Cary Eclipse fluorometer with an excitation wavelength of 475 nm and emission scanned between 500 and 600 nm. The fluorescence intensity at wavelength of 540 nm was read. The results are shown in Figure 14, which demonstrates that fluorescence increased with the increase of maltose concentration in the range of 0 to about 9.4 mM maltose.
  • the maltose binding constant K d for the MBP hydrogel biosensor prepared by the two-pot method was calculated to be about 0.869 mM, using the methods of K d calculation described in Example 9. Again, the encapsulation or entrapment of binding protein caused an unexpected shift of more than an order of magnitude in Kd compared to solution.
  • HEMA 2-Hydroxyethyl methacrylate
  • MAA methacrylic acid
  • Triethylene glycol dimethacrylate (TEGDMA) and polyethylene glycol (400) dimethacrylate (PEGDMA) were purchased from Sartomer, Exton, PA.
  • l-Ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), benzoyl peroxide (BPO) and dimethylformamide (DMF) were purchased from Aldrich, Milwaukee, WI.
  • swelling was determined by measuring the hydrogel disk volume changes before and after being soaked in water for one day. The disk volumes were measured by placing them in a graduated cylinder and measuring displaced water volume.
  • HEMA 7.7 mmol
  • MAA MAA
  • TEGDMA 24 mg
  • BPO 21 mg
  • BPO BPO
  • the molar ratio of HEMA:MAA was about 9:1, and the total monomer weight concentration (HEMA, MAA, TEGDMA) was about 70%.
  • the mixture was deoxygenated by argon gas purging for about 5 minutes.
  • the solution was the transferred to 1 ml polypropylene syringes and capped. The syringes were incubated at 7O 0 C for about 90 minutes.
  • hydrogels Upon cooling, cylinder-shape hydrogels were removed from the syringes and sectioned into disks of about 4 mm diameter by 2 mm thickness. The disks were soaked in distilled water for two days to remove low molecular weight impurities. Additional examples of hydrogels prepared in accordance with the above described method are summarized in Table 8.
  • Example 22 Entrapment of Binding Protein in HEMA-MAA Hydrogel
  • HEMA-MAA hydrogels were synthesized using different HEMA/MAA molar ratio, crosslinker contents, crosslinker types, and reaction times.
  • NBD labeled GBP stock solution was prepared.
  • 1 mg of IANBD labeled GBP was dissolved in 2.5 ml 0.1 MES buffer (pH 6.5).
  • the hydrogel disks were soaked overnight in aqueous solutions containing the mutant GGBP-NBD.
  • the hydrogel biosensors were placed in the wells of a black 96 well plate along with 180 ⁇ L PBS buffer per disk, and the initial fluorescence intensities were measured using a CytoFluor fluorescence multi-well plate reader (excitation and emission filters were centered at 485 nm and 530 nm, respectively).
  • 20 ⁇ L of 1 M glucose /water solution was added into each well, providing a final glucose concentration of 100 niM.
  • the fluorescence intensity changes were recorded again after the solution was equilibrated for 20 minutes to allow glucose to completely diffuse into the hydrogel disks and bind with GGBP.
  • Table 8 demonstrates that the poly(HEMA) hydrogel glucose biosensors prepared by the method described were responsive to glucose.
  • Table 8 further summarizes the determined swelling data of different HEMA-MAA hydrogel formulations synthesized in aqueous phase.
  • Example 23 Covalently Immobilized Binding Protein in Aqueous Phase Synthesized HEMA-MAA Hydrogels
  • This example describes the coupling of a binding protein to the HEMA-MAA copolymer hydrogel as prepared in Example 21.
  • Hydrogel disks as prepared in Example 21 were exposed to a bulk solution of 0.5mg mutant GGBP in 300 ⁇ l of 0.1M MES buffer solution and stored refrigerated overnight. A sample of disks and bulk solution (200 ul) was mixed with an equal volume ratio of EDC/NHS mixture. Various concentrations of EDC were tested for the protein coupling reaction, with the EDC/NHS ration being held constant at 4:1. The protein-hydrogel matrix coupling was continued at room temperature for 4 hours. The disks were removed and exposed to ethanolamine (IM, pH 8.5) for 1 hour to quench the coupling reaction.
  • IM ethanolamine
  • Example 25 Covalently Immobilized Binding Protein to HEMA-MAA Hydrogel
  • NBD was covalently immobilized within the HEMA-MAA hydrogels of the previous example, which were prepared in organic solvent phase.
  • the glucose response of the formed hydrogel disks was tested in a 96 well plate using a Varian Caty Eclipse fluorometer with an excitation wavelength of 475 nm and emission scanned between 500 and 600 mn.
  • the hydrogel glucose biosensor prepared according to the procedures herein, provided a functional biosensor having a QF of about 4.1.
  • changes in fluorescence of the hydrogel glucose biosensor correlated to changes in glucose concentrations in solution. The fluorescence increased with the increase of glucose concentration in the range of 0 to 100 mM glucose.
  • the glucose binding constant Kd for the hydrogel glucose biosensor was calculated to be about 5 mM, using methods previously described herein.
  • Example 26 The effect of the Cross-linker and Monomer Concentration, and Monomer Ratio on Fluorescence Response of the Hydrogel Biosensor
  • Hydrogel biosensors comprising varying amounts of monomer concentration, HEMA/MAA molar ratios, and crosslinking agents were prepared in organic solvent by the methods illustrated in Example 24 and the protein was covalently immobilized in hydrogels by methods illustrated in Example 23.
  • the glucose responses of the hydrogel biosensors were tested using a Varian Cary Eclipse fluorometer as taught in the previous examples herein.
  • Table 10 shows the binding response of hydrogel biosensors over a range of different monomer concentrations, HEMA/MAA molar ratios, and crosslinker contents.
  • hydrogel glucose biosensors prepared according to the methods of the present invention with a monomer concentration of 20% have higher QF values than hydrogels prepared with monomer concentration of 50%.
  • Example 27 Effect of Protein Loading, EDC Concentration, and Coupling Time to Organic Phase Synthesized HEMA-MAA Hydrogels.
  • This example describes how protein loading concentration, EDC concentration and reaction time affect the glucose response of hydrogel glucose biosensors.
  • the HEMA-MAA hydrogel was prepared similarly to experiment no. 1 in Example 26 and exposed to different concentrations of GGBP-NBD in 0.1 M MES buffer overnight.
  • the hydrogel disks, in the GGBP-NBD/MES solution, were then soaked with equal volumes of EDC/NHS solution mixture (10-30 mM EDC, EDC/NHS concentration ratio 4:1).
  • the protein-hydrogel coupling reaction was continued for 2-4 hours at room temperature.
  • the disks were then exposed to ethanolamine (IM, pH 8.5) for 0.5 hour to quench the protein-hydrogel coupling reaction.
  • Example 28 Stability of the Hydrogel Glucose Biosensors
  • This example illustrates the stability of hydrogel disks prepared by the methods of Examples 21 and 24. Two hydrogel disks with immobilized GGBP-NBD were stored in 20 mL PBS solution (pH 7.4) at room temperature. At varying time intervals, glucose binding response (QF) was determined, and the results are depicted in Table 12.
  • Table 12 Stability of Hydro el Glucose Biosensors
  • the fiber/needle bevel was removed from the syringe.
  • the optical fiber tip contained a thin hydrogel film having a thickness of about 100 to about 500 ⁇ m.
  • the matrix was washed overnight with water (200 ⁇ L) in a capped vial.
  • the fiber was then inserted into 50 ⁇ l of GGBP-NBD solution (18 ⁇ M protein concentration, dye/protein ratio was 1.1) in 0.1 M MES buffer and the labeled protein was allowed to infuse for 2 hours.
  • the resultant biosensor probe was then soaked in 200 ⁇ l PBS buffer for two days before use/testing.
  • Monitoring changes in glucose concentration on a continuing basis using the fiber optic- hydrogel biosensor was achieved using a fiuorometer.
  • the fluorometer comprised a 470 nm LED light source having a dichroic filter to reflect the 470 nm excitation towards the input end of the fiber.
  • the transmitted fluorescence from the fiber tip containing the hydrogel was directed through a 550 nm bandpass filter.
  • hydrogel glucose biosensors described herein were also used to track in vivo glucose concentration changes in anesthetized Yorkshire swine pigs.
  • the pigs were sedated using a mixture of Telazol, Ketamine, and Rompin.
  • An endotracheal tube was inserted and the pig was given Isofluorane to maintain anesthesia.
  • a chest catheter was placed in either the vena cava or the carotid artery for blood sampling and an IV catheter was placed in the ear for maintenance fluid delivery, glucose delivery and control.
  • Optical fiber-hydrogel glucose biosensors prepared as described above, in 21 gauge needles, were inserted intradermally, bevel down, and taped securely. A surface skin probe was taped on skin within 1 inch of the sensors to monitor temperature. Sampling via the sensor with simultaneously blood sampling was begun and continued at 10 minute intervals. Alternating solutions of lactated ringer's solution, with and without 10% dextrose, were infused through the ear vein of the pig to increase and decrease glucose levels in a controllable fashion. The blood samples were obtained from the vena cava of the pig through a chest catheter, and blood sugar readings were tested on a handheld blood glucose meter. When data collection was complete, the sensors were removed and placed in buffer solution.
  • Figure 19 depicts the changes in fluorescence intensity of the hydrogel glucose biosensors in response to changing blood glucose levels in the glucose-controlled anesthetized pig. This data demonstrates, among other attributes, the reversible and continuous monitoring utility of the optical fiber-hydrogel sensor described herein.
  • Example 30 Hydrogel Glucose Biosensor Formation using Photo Crosslinking
  • mutant GGBP E149C/A213R/L238S was labeled with IANBD and purified to provide a protein concentration of 10.4 ⁇ M, and a dye/protein ratio 1.0.
  • PEGDMA poly(ethylene glycol) dimethacrylate 1000
  • 6-arm PEG with acrylate terminations Biolink Life Sciences, Cary, NC, USA
  • 2-Hydroxy-2-methylpropiophenone Sigma
  • sorbitol Sigma
  • 450 ⁇ L of PBS PBS
  • the mixture was vortexed for about 15 seconds and 150 ⁇ L of GGBP-NBD was then added to the solution.
  • the mixture was then injected in between two glass plates separated by a 1 mm spacer and exposed to UV light (450 watts at 22cm) for 3.5 minutes. After the reaction was complete, the hydrogel sheets were punched into 5 mm diameter disks with a dermal biopsy punch.
  • the responsiveness of the hydrogel glucose biosensors was assessed. Fluorescence was measured using a CytoFluor fluorescence multi-well plate reader (excitation and emission filters were centered at 485 nm and 530 nm, respectively). The hydrogel biosensors were placed in the wells of a black 96 well plate along with 180 ⁇ L PBS buffer per disk and fluorescence was measured. Next, 20 ⁇ L of 1 M glucose /water solution was added into each well, providing a final glucose concentration of 100 mM and fluorescence intensity changes were recorded again after the solution was equilibrated for 20 minutes to allow glucose to completely diffuse into the hydrogel disks and bind with GGBP.
  • Figure 20 demonstrates that hydrogel glucose biosensors prepared by the photo crosslinking methods described herein were responsive to glucose. Figure 20 also shows that the hydrogels were stable for at least 7 days after formation and that the hydrogels were responsive both before and after lyophilization and rehydration. [00168]
  • Example 31 Functional Derivatization of Binding Protein by Reaction -with Reactive Groups
  • Providing acrylate functionality is but one example of derivatizing a fluorescent labeled binding protein with a reactive moiety.
  • N- acryloxy succidimide Aldrich Chemicals
  • ImL of a lmg/mL of E149C/A213R/L238S fluorescent labeled mutant binding protein A ratio of 10 parts N- acryloxy succidimide to 1 parts protein was used in this experiment.
  • the reaction mixture was eluted through a NAP 10 column with collection of the second fraction.
  • the collected derivatized binding protein was used in subsequent hydrogel polymerization reactions as described infra. It is understood that ratios of reactive moiety to protein can be optimally varied so long as the resultant derivatized protein maintains its binding functionality before or after polymerization.
  • Glucose response and Qf values were obtained and compared to solution values of non-derivatized protein.
  • Qf values of the derivatized protein co-polymerized into the hydrogel were about 85% of a non- derivatized protein in solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

La présente invention a trait à des protéines de liaison, des protéines comportant des groupes rapporteurs, des compositions de molécules le liaison comportant des groupes rapporteurs dans des matrices perméables d'analytes, et à leur utilisation en tant que biocapteurs in vitro et in vivo.
PCT/US2006/008175 2005-03-11 2006-03-09 Proteine de liaison piegee en tant que biocapteurs WO2006096746A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/077,028 2005-03-11
US11/077,028 US20050239155A1 (en) 2002-01-04 2005-03-11 Entrapped binding protein as biosensors

Publications (1)

Publication Number Publication Date
WO2006096746A1 true WO2006096746A1 (fr) 2006-09-14

Family

ID=36953715

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/008175 WO2006096746A1 (fr) 2005-03-11 2006-03-09 Proteine de liaison piegee en tant que biocapteurs

Country Status (1)

Country Link
WO (1) WO2006096746A1 (fr)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009118492A1 (fr) * 2008-03-25 2009-10-01 L'oreal Polymere ethylenique statistique comprenant un groupe reactif et un groupe silicone, composition cosmetique et procede de traitement cosmetique
US7682338B2 (en) 2006-08-23 2010-03-23 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US7686787B2 (en) 2005-05-06 2010-03-30 Medtronic Minimed, Inc. Infusion device and method with disposable portion
US7736344B2 (en) 2006-08-23 2010-06-15 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US7794434B2 (en) 2006-08-23 2010-09-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7811262B2 (en) 2006-08-23 2010-10-12 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7828764B2 (en) 2006-08-23 2010-11-09 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7959715B2 (en) 2007-04-30 2011-06-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US7963954B2 (en) 2007-04-30 2011-06-21 Medtronic Minimed, Inc. Automated filling systems and methods
US8025658B2 (en) 2007-04-30 2011-09-27 Medtronic Minimed, Inc. Adhesive patch systems and methods
US8137314B2 (en) 2006-08-23 2012-03-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with compressible or curved reservoir or conduit
US8187228B2 (en) 2006-08-23 2012-05-29 Medtronic Minimed, Inc. Infusion pumps and methods and delivery devices and methods with same
US8277415B2 (en) 2006-08-23 2012-10-02 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8303574B2 (en) 2006-02-09 2012-11-06 Deka Products Limited Partnership Adhesive and peripheral systems and methods for medical devices
US8323250B2 (en) 2007-04-30 2012-12-04 Medtronic Minimed, Inc. Adhesive patch systems and methods
US8414563B2 (en) 2007-12-31 2013-04-09 Deka Products Limited Partnership Pump assembly with switch
US8434528B2 (en) 2007-04-30 2013-05-07 Medtronic Minimed, Inc. Systems and methods for reservoir filling
US8496646B2 (en) 2007-02-09 2013-07-30 Deka Products Limited Partnership Infusion pump assembly
US8512288B2 (en) 2006-08-23 2013-08-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8597243B2 (en) 2007-04-30 2013-12-03 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US8613725B2 (en) 2007-04-30 2013-12-24 Medtronic Minimed, Inc. Reservoir systems and methods
US8840586B2 (en) 2006-08-23 2014-09-23 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US20170081636A1 (en) * 2015-09-22 2017-03-23 Qt Holdings Corp Methods and compositions for activation or expansion of t lymphocytes
US10739338B2 (en) 2014-03-24 2020-08-11 Qt Holdings Corp Shaped articles including hydrogels and methods of manufacture and use thereof
CN113484525A (zh) * 2021-07-05 2021-10-08 海南医学院 一种肝素结合蛋白(hbp)时间分辨荧光免疫层析半定量检测试纸条
US11364335B2 (en) 2006-02-09 2022-06-21 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11395877B2 (en) 2006-02-09 2022-07-26 Deka Products Limited Partnership Systems and methods for fluid delivery
US11404776B2 (en) 2007-12-31 2022-08-02 Deka Products Limited Partnership Split ring resonator antenna adapted for use in wirelessly controlled medical device
US11426512B2 (en) 2006-02-09 2022-08-30 Deka Products Limited Partnership Apparatus, systems and methods for an infusion pump assembly
US11478623B2 (en) 2006-02-09 2022-10-25 Deka Products Limited Partnership Infusion pump assembly
US11497686B2 (en) 2007-12-31 2022-11-15 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11497846B2 (en) 2006-02-09 2022-11-15 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
US11523972B2 (en) 2018-04-24 2022-12-13 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11524151B2 (en) 2012-03-07 2022-12-13 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11534542B2 (en) 2007-12-31 2022-12-27 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11597541B2 (en) 2013-07-03 2023-03-07 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11642283B2 (en) 2007-12-31 2023-05-09 Deka Products Limited Partnership Method for fluid delivery
US11723841B2 (en) 2007-12-31 2023-08-15 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11890448B2 (en) 2006-02-09 2024-02-06 Deka Products Limited Partnership Method and system for shape-memory alloy wire control
US11964126B2 (en) 2006-02-09 2024-04-23 Deka Products Limited Partnership Infusion pump assembly

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197534B1 (en) * 1998-07-17 2001-03-06 Joseph R. Lakowicz Engineered proteins for analyte sensing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197534B1 (en) * 1998-07-17 2001-03-06 Joseph R. Lakowicz Engineered proteins for analyte sensing

Cited By (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935085B2 (en) 2005-05-06 2011-05-03 Medtronic Minimed, Inc. Infusion device and method with disposable portion
US9180248B2 (en) 2005-05-06 2015-11-10 Medtronic Minimed, Inc. Infusion device with base portion and durable portion
US9233203B2 (en) 2005-05-06 2016-01-12 Medtronic Minimed, Inc. Medical needles for damping motion
US7686787B2 (en) 2005-05-06 2010-03-30 Medtronic Minimed, Inc. Infusion device and method with disposable portion
US7699833B2 (en) 2005-05-06 2010-04-20 Moberg Sheldon B Pump assembly and method for infusion device
US10220143B2 (en) 2005-05-06 2019-03-05 Medtronic Minimed, Inc. Infusion device with base portion and durable portion
US11141530B2 (en) 2005-05-06 2021-10-12 Medtronic Minimed, Inc. Infusion device with base portion and durable portion
US7955305B2 (en) 2005-05-06 2011-06-07 Medtronic Minimed, Inc. Needle inserter and method for infusion device
US8529553B2 (en) 2005-08-23 2013-09-10 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US11738139B2 (en) 2006-02-09 2023-08-29 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
US11395877B2 (en) 2006-02-09 2022-07-26 Deka Products Limited Partnership Systems and methods for fluid delivery
US11559625B2 (en) 2006-02-09 2023-01-24 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
US11534543B2 (en) 2006-02-09 2022-12-27 Deka Products Limited Partnership Method for making patch-sized fluid delivery systems
US11690952B2 (en) 2006-02-09 2023-07-04 Deka Products Limited Partnership Pumping fluid delivery systems and methods using force application assembly
US11786651B2 (en) 2006-02-09 2023-10-17 Deka Products Limited Partnership Patch-sized fluid delivery system
US11497846B2 (en) 2006-02-09 2022-11-15 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
US11478623B2 (en) 2006-02-09 2022-10-25 Deka Products Limited Partnership Infusion pump assembly
US11426512B2 (en) 2006-02-09 2022-08-30 Deka Products Limited Partnership Apparatus, systems and methods for an infusion pump assembly
US11413391B2 (en) 2006-02-09 2022-08-16 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
US11408414B2 (en) 2006-02-09 2022-08-09 Deka Products Limited Partnership Adhesive and peripheral systems and methods for medical devices
US11617826B2 (en) 2006-02-09 2023-04-04 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
US11364335B2 (en) 2006-02-09 2022-06-21 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11339774B2 (en) 2006-02-09 2022-05-24 Deka Products Limited Partnership Adhesive and peripheral systems and methods for medical devices
US11890448B2 (en) 2006-02-09 2024-02-06 Deka Products Limited Partnership Method and system for shape-memory alloy wire control
US11904134B2 (en) 2006-02-09 2024-02-20 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
US9259531B2 (en) 2006-02-09 2016-02-16 Deka Products Limited Partnership Adhesive and peripheral systems and methods for medical devices
US8303574B2 (en) 2006-02-09 2012-11-06 Deka Products Limited Partnership Adhesive and peripheral systems and methods for medical devices
US11964126B2 (en) 2006-02-09 2024-04-23 Deka Products Limited Partnership Infusion pump assembly
US11992650B2 (en) 2006-02-09 2024-05-28 Deka Products Limited Partnership Adhesive and peripheral systems and methods for medical devices
US8414522B2 (en) 2006-02-09 2013-04-09 Deka Products Limited Partnership Fluid delivery systems and methods
US8998850B2 (en) 2006-02-09 2015-04-07 Deka Products Limited Partnership Adhesive and peripheral systems and methods for medical devices
US8585377B2 (en) 2006-02-09 2013-11-19 Deka Products Limited Partnership Pumping fluid delivery systems and methods using force application assembly
US8545445B2 (en) 2006-02-09 2013-10-01 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
US8187228B2 (en) 2006-08-23 2012-05-29 Medtronic Minimed, Inc. Infusion pumps and methods and delivery devices and methods with same
US7789857B2 (en) 2006-08-23 2010-09-07 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US8512288B2 (en) 2006-08-23 2013-08-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US7682338B2 (en) 2006-08-23 2010-03-23 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US8475432B2 (en) 2006-08-23 2013-07-02 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US8444607B2 (en) 2006-08-23 2013-05-21 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US7736338B2 (en) 2006-08-23 2010-06-15 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US7736344B2 (en) 2006-08-23 2010-06-15 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US7744589B2 (en) 2006-08-23 2010-06-29 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8840586B2 (en) 2006-08-23 2014-09-23 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US8840587B2 (en) 2006-08-23 2014-09-23 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US8226615B2 (en) 2006-08-23 2012-07-24 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US7794434B2 (en) 2006-08-23 2010-09-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US8202250B2 (en) 2006-08-23 2012-06-19 Medtronic Minimed, Inc. Infusion pumps and methods and delivery devices and methods with same
US8277415B2 (en) 2006-08-23 2012-10-02 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US7811262B2 (en) 2006-08-23 2010-10-12 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7828764B2 (en) 2006-08-23 2010-11-09 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7905868B2 (en) 2006-08-23 2011-03-15 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8137314B2 (en) 2006-08-23 2012-03-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with compressible or curved reservoir or conduit
US8172804B2 (en) 2006-08-23 2012-05-08 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US8496646B2 (en) 2007-02-09 2013-07-30 Deka Products Limited Partnership Infusion pump assembly
US8323250B2 (en) 2007-04-30 2012-12-04 Medtronic Minimed, Inc. Adhesive patch systems and methods
US7959715B2 (en) 2007-04-30 2011-06-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US10772796B2 (en) 2007-04-30 2020-09-15 Medtronic Minimed, Inc. Automated filling systems and methods
US8597270B2 (en) 2007-04-30 2013-12-03 Medtronic Minimed, Inc. Automated filling systems and methods
US9980879B2 (en) 2007-04-30 2018-05-29 Medtronic Minimed, Inc. Automated filling systems and methods
US8597243B2 (en) 2007-04-30 2013-12-03 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US8172929B2 (en) 2007-04-30 2012-05-08 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US9901514B2 (en) 2007-04-30 2018-02-27 Medtronic Minimed, Inc. Automated filling systems and methods
US8613725B2 (en) 2007-04-30 2013-12-24 Medtronic Minimed, Inc. Reservoir systems and methods
US8434528B2 (en) 2007-04-30 2013-05-07 Medtronic Minimed, Inc. Systems and methods for reservoir filling
US8083716B2 (en) 2007-04-30 2011-12-27 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US8025658B2 (en) 2007-04-30 2011-09-27 Medtronic Minimed, Inc. Adhesive patch systems and methods
US7963954B2 (en) 2007-04-30 2011-06-21 Medtronic Minimed, Inc. Automated filling systems and methods
US9522225B2 (en) 2007-04-30 2016-12-20 Medtronic Minimed, Inc. Adhesive patch systems and methods
US11723841B2 (en) 2007-12-31 2023-08-15 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US8414563B2 (en) 2007-12-31 2013-04-09 Deka Products Limited Partnership Pump assembly with switch
US8491570B2 (en) 2007-12-31 2013-07-23 Deka Products Limited Partnership Infusion pump assembly
US11534542B2 (en) 2007-12-31 2022-12-27 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11894609B2 (en) 2007-12-31 2024-02-06 Deka Products Limited Partnership Split ring resonator antenna adapted for use in wirelessly controlled medical device
US9526830B2 (en) 2007-12-31 2016-12-27 Deka Products Limited Partnership Wearable pump assembly
US11404776B2 (en) 2007-12-31 2022-08-02 Deka Products Limited Partnership Split ring resonator antenna adapted for use in wirelessly controlled medical device
US11497686B2 (en) 2007-12-31 2022-11-15 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11642283B2 (en) 2007-12-31 2023-05-09 Deka Products Limited Partnership Method for fluid delivery
US11701300B2 (en) 2007-12-31 2023-07-18 Deka Products Limited Partnership Method for fluid delivery
WO2009118492A1 (fr) * 2008-03-25 2009-10-01 L'oreal Polymere ethylenique statistique comprenant un groupe reactif et un groupe silicone, composition cosmetique et procede de traitement cosmetique
FR2929279A1 (fr) * 2008-03-25 2009-10-02 Oreal Polymere ethylenique statistique comprenant un groupe reactif et un groupe silicone, composition cosmetique et procede de traitement cosmetique
US11524151B2 (en) 2012-03-07 2022-12-13 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11597541B2 (en) 2013-07-03 2023-03-07 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US10739338B2 (en) 2014-03-24 2020-08-11 Qt Holdings Corp Shaped articles including hydrogels and methods of manufacture and use thereof
US9790467B2 (en) * 2015-09-22 2017-10-17 Qt Holdings Corp Methods and compositions for activation or expansion of T lymphocytes
US20170081636A1 (en) * 2015-09-22 2017-03-23 Qt Holdings Corp Methods and compositions for activation or expansion of t lymphocytes
US11523972B2 (en) 2018-04-24 2022-12-13 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
CN113484525A (zh) * 2021-07-05 2021-10-08 海南医学院 一种肝素结合蛋白(hbp)时间分辨荧光免疫层析半定量检测试纸条

Similar Documents

Publication Publication Date Title
WO2006096746A1 (fr) Proteine de liaison piegee en tant que biocapteurs
US20050239155A1 (en) Entrapped binding protein as biosensors
EP1458760B1 (fr) Proteines de liaison piegees en tant que biocapteurs
AU2004237079B2 (en) Multicoated or multilayer entrapment matrix for protein biosensor
AU2005313564B2 (en) Sensor for detection of carbohydrate
US8778635B2 (en) Thermostable proteins and methods making and using thereof
CA2590341A1 (fr) Capteur de detection d'hydrates de carbone
WO2003057851A2 (fr) Proteines de liaison en tant que biocapteurs
WO2005080988A1 (fr) Proteines de liaison utiles comme biocapteurs
WO2008131361A2 (fr) Biocapteurs pour mesurer des analytes dans le liquide interstitiel
WO2007065653A1 (fr) Polymère flexible portant des hydrates de carbone
AU2012216832B2 (en) Thermostable proteins and methods of making and using thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06737355

Country of ref document: EP

Kind code of ref document: A1